Track market-moving stories before they get noisy

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce and engagement, today announced a worldwide reseller agreement with Mastercard, establishing a new distribution channel for Rezolve Ai’s technology as businesses prepare for the next generation of AI-driven commerce.

Under the agreement, Mastercard is authorized to market, offer and sell subscriptions to Rezolve Ai’s software and SaaS services worldwide on a non-exclusive basis. The arrangement provides a commercial framework for bringing Rezolve Ai’s capabilities to Mastercard customers with Mastercard leading coordination of the sales process and contracting directly with resale customers.

The agreement covers capabilities spanning conversational commerce, intelligent search and product discovery, catalogue enrichment, personalization, recommendations and cart and checkout orchestration. Together, these technologies help businesses connect customer intent with relevant products and support shopping journeys from discovery through checkout handoff.

Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai, said:
“This agreement gives Rezolve Ai a powerful new engine for international growth. Mastercard can market and sell our technology worldwide, with a defined commercial framework for turning customer opportunities into deployments and subscription revenues.

“As AI agents change how people shop, merchants need technology that understands their products, represents them accurately and helps turn demand into purchases. Rezolve Ai provides that intelligence.

“We are building Rezolve Ai to become essential infrastructure for agentic commerce. This agreement is a major step in taking our technology to market at scale.”

A worldwide distribution framework
The reseller agreement provides for coordinated sales activity, including joint customer evaluations, presentations, proposals and product demonstrations, supported by Rezolve Ai’s technical expertise.

For Rezolve Ai, the arrangement creates an opportunity to extend its commercial reach through Mastercard-led customer relationships. Individual deployments, including the selected capabilities, geography and commercial terms, will be agreed through separate statements of work.

Technology for the next generation of commerce
As shopping becomes increasingly conversational and agent-driven, businesses need systems that can interpret customer requests, organize and enrich product information, personalize recommendations and coordinate the steps towards purchase.

Rezolve Ai’s technology addresses these requirements across the merchant experience. The agreement also encompasses policy controls, governance and analytics capabilities designed to support deployment within customer-defined operating requirements.

“The opportunity is to make AI-powered commerce work for businesses at scale,” Wagner added. “We believe combining our commerce intelligence with this new worldwide distribution channel can help accelerate adoption and establish Rezolve Ai at the center of that transformation.”

About Rezolve Ai

Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Global Head of Communications
[email protected]
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the expected benefits of Rezolve Ai’s worldwide reseller agreement with Mastercard, potential customer opportunities, international expansion, adoption of the Company’s technology, growth in software and SaaS subscription revenues, and the development of agentic commerce.

These statements reflect management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These include the parties’ ability to convert sales opportunities into signed statements of work and deployments; the timing and extent of customer adoption; demand for the Company’s solutions; competition; technological and regulatory developments; and other risks described in the Company’s filings with the Securities and Exchange Commission. The reseller agreement does not guarantee customer orders, minimum purchase volumes or revenues.

Forward-looking statements speak only as of the date of this release. Rezolve Ai undertakes no obligation to update them, except as required by law.

DETROIT — General Motors plans to introduce hybrid models into its U.S. lineup as sales of the vehicles continue to grow amid inflated gas prices and a pullback in all-electric cars.

Mike Anderson, GM's vice president of propulsion engineering, reconfirmed the automaker's hybrid plans, but declined to discuss timing for such vehicles, which had previously been expected as soon as next year.

"It's fair to say that [hybrids are] part of the plan," Anderson, a 35-year GM veteran, told CNBC during an interview. "We're not tone deaf to our customers. We know what they want and we want to give that to them as quickly as we can."

GM has largely been absent from the hybrid market this decade, instead using its resources to go "all-in" on all-electric vehicles. But amid lackluster EV demand, industry deregulation and increased hybrid popularity, Anderson said the company needs to meet customer demand wherever it may be.

"Our long-term vision is an all-electric future. That's our goal," Anderson said. "That's the end state, but it's going to be a journey that involves technology diversity."

GM CEO Mary Barra in January said the automaker was still studying plug-in hybrid electric vehicles, or PHEVs, for its U.S. lineup as well as traditional hybrids but remained critical of the technologies. She also told Bloomberg later that month that a "handful" of such models were coming but did not give a timeline.

In mid-2024, GM announced plans to introduce PHEVs by 2027. At that time, GM was under pressure to meet stricter federal tailpipe emissions standards that have since been lowered or eliminated by the Trump administration.

watch now

AutoForecast Solutions, an automotive data and consulting firm, expects GM to begin offering PHEVs in late 2027 to early 2028 with a 70-mile EV range "throughout its portfolio," according to Casey Selecman, director of powertrain forecasts for the company.

"GM has several PHEVs planned throughout the portfolio from the Equinox to the Silverado but has been very cautious in rolling them out due to fears of customer technology preference changes that have burned them in the past," he said.

Anderson declined to discuss potential products or timing for GM's first new hybrid model.

"You can see, without me saying what our future plans are, where the customers are clamoring for these things and really, really going for them," he said. "We want to meet them where they want things."

Sales of hybrid models in the U.S. have jumped amid dimming EV demand, inflated gas prices and more offerings in the market, which GM has been missing out on.

Cox Automotive reports hybrid vehicle sales from the second quarter of this year increased 23% from a year earlier to represent a record 16.3% of U.S. sales from April through June. That compares with roughly 5.8% of sales for EVs, Cox said.

EV/Hybrid vehicle types

The automotive industry has more powertrain and "propulsion" options than ever before. Here's a breakdown:Internal combustion engine (ICE): A "traditional" vehicle with an engine that's fueled with gasoline or diesel.Mild-hybrid electric vehicle (MHEV): An ICE vehicle that functions largely like a nonhybrid vehicle but may include minimal electrified features such as a small battery, regenerative braking or electric motor.Hybrid electric vehicle (HEV): Think of the Toyota Prius, a vehicle that has a hybrid powertrain system combined with an engine.Plug-in hybrid electric vehicle (PHEV): These vehicles feature an internal combustion engine combined with a hybrid system, including a larger battery than traditional hybrid vehicles as well as a plug to recharge the vehicle's battery. They typically allow drivers to travel a certain number of miles using the battery before the engine is needed to power the car or truck.Battery-electric vehicle (BEV): These all-electric vehicles do not feature an internal combustion engine. Instead, they contain an electric motor that's powered by a large battery. They need to be recharged using an electrical outlet and charging port or charging station.Fuel cell electric vehicle (FCEV): Hydrogen fuel cell electric vehicles and equipment operate much like BEVs but are powered by electricity generated from hydrogen and oxygen instead of pure batteries, which commonly include lithium. They're filled up with a nozzle, similar to traditional gas and diesel vehicles.Extended-range electric vehicles (EREV): These are an emerging technology that largely function as a PHEV, however after the battery runs out of energy to power the vehicle, an engine works as a generator to exclusively power electric motors. The vehicle still drives like an EV instead of having the engine directly power the vehicle's motion.There are a growing number of hybrid variants being introduced by automakers but, in general, those vehicles combine a traditional gas-powered engine with electric motors and a battery to offer better fuel economy and, in many cases, better performance.

The fastest-growing segments for hybrids in the U.S. are compact crossover/SUV and mid-size vehicles, according to Cox.

"Hybrid vehicles continue to be the clearest growth story in the electrified market," Stephanie Valdez Streaty, Cox director of industry insights, said during a presentation last week.

There are currently a few types of hybrids available in the U.S. Traditional hybrids, like a Toyota Prius, feature many electrified engine technologies, while PHEVs have a designated all-electric range before using an engine to power the vehicle.

Then there are extended-range electric vehicles, or "series hybrids," that drive like an EV but have an engine that essentially operates like a generator to power electric motors to propel a vehicle.

The combination of two powertrains adds additional complexity and costs, which has been an argument GM has made against hybrids, but it's something many consumers appear willing to pay for as hybrid sales continue to rise.

GM currently offers only one hybrid, a model of its Chevrolet Corvette. The Detroit automaker's last true push into hybrids was the Chevrolet Volt plug-in, which was discontinued in 2019.

GM's crosstown rivals, Ford Motor and Chrysler parent Stellantis, have leaned on suppliers to get hybrid vehicles to market more quickly.

Anderson said GM's strategy "will be a mix" of internal and external technologies based on cost, segment and product.

"We're deliberate because, usually for strategic reasons, we need to control our own destiny. We need to control our own timing," he said. "Or, if it's commodity, go get it. Go get the best price you can."

Key Takeaways Dow is benefiting from high-return growth projects, cost actions and advantaged feedstock positions.DOW expects more than $1.3 billion of self-help benefits in 2026, including $700 million from its initiative.Dow faces soft demand, seasonal construction weakness and higher energy and feedstock costs. Dow Inc. (DOW - Free Report) benefits from cost and productivity initiatives, growth actions in attractive markets, and an advantaged feedstock position amid a challenging macroeconomic backdrop.

The company’s shares have gained 19.5% over a year compared with the Zacks Chemicals Diversified industry’s 4.6% decline.

Image Source: Zacks Investment Research

Let’s find out why DOW stock is worth retaining at the moment.

DOW Gains on High-Return Growth Projects & Self-Help ActionsDow is well positioned with its differentiated portfolio and advantaged feedstock positions in the Americas. It remains focused on investing in attractive areas. Its broad portfolio, significant low-cost feedstock positions, global footprint and market reach place it in an advantageous position against competitors. While Dow faces headwinds from heightened macroeconomic and geopolitical uncertainties, it remains focused on growth actions in attractive end markets and executing high-return incremental growth projects in cost-advantaged regions.

Recent alkoxylation investments are contributing to growth in the Industrial Solutions business. The company is also expanding specialty silicones capabilities for mobility, electronics and healthcare, while increasing its emphasis on higher-value downstream applications. Dow has completed the shutdown of its higher-cost Barry, U.K., upstream siloxanes unit, shifting its silicones mix by more than 25% toward more stable and higher-margin businesses while maintaining value-chain integration.

The Barry action is expected to provide about $60 million of EBITDA uplift in the second half of 2026. Dow also restarted its lowest-cost and most flexible European cracker in Terneuzen and remains on track to shut the Bohlen cracker by year-end 2027, actions aimed at improving its cost-curve position and regional flexibility. The Alberta project continues to progress on its revised timeline, with roughly 60% of capital expenditures already spent, most critical labor contracts awarded and incentives intact.

Dow continues to emphasize cost and operational discipline through restructuring, productivity and process simplification. The company materially completed its $1 billion 2025 cost program and delivered more than $300 million of in-period self-help benefits in the second quarter of 2026. It now expects more than $1.3 billion of total self-help benefits in 2026. DOW has launched the “Transform to Outperform” initiative to improve productivity, reduce complexity, streamline its end-to-end processes and enable improved returns. The initiative is expected to contribute about $700 million in 2026.

Strong Financial Health Supports Capital AllocationDOW has a strong balance sheet and generates substantial cash flows, which enable it to finance its growth investments in higher-value businesses and regions, and drive shareholder value. The company maintained about $14 billion of available liquidity at the end of the second quarter, and has no substantive debt maturities until 2029. Management plans to direct excess cash toward deleveraging and expects more than $500 million of working-capital release in the second half of 2026.

Dow generated $1.3 billion of cash from operating activities in the second quarter, versus a $470 million use of cash in the year-ago period. The company returned $253 million to shareholders through dividends in the quarter. Management expects working-capital actions to support cash conversion.

Soft Demand and Cost Pressures Ail DOWDow remains exposed to weak and inconsistent demand across several regions and end markets. Packaging demand is resilient globally, and U.S. consumer spending has held up, but the U.S. housing market remains weak because of affordability concerns and high mortgage rates. In Europe, structural operating and labor costs persist despite emerging government support and trade protection measures.

In Asia Pacific, industrial production and manufacturing activity have improved, but consumer demand remains soft and uneven. Middle East tensions and constrained shipping also continue to disrupt supply chains. These conditions were visible in second-quarter 2026 volumes, which fell 1% year over year at the company level. DOW expects a normal seasonal decline in building and construction demand in the third quarter, along with lower seasonal coatings demand.

Dow remains sensitive to energy and raw-material volatility. The Middle East conflict has kept logistics constrained and traffic through the Strait of Hormuz below historical levels, supporting higher risk premiums for energy and feedstocks. Management described the third-quarter environment as supportive but higher cost and noted that crude oil and key feedstocks had risen sharply. Elevated feedstock and energy costs are likely to impact margins in the third quarter.

DOW’s Zacks Rank & Other Key PicksDOW currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Ternium S.A. (TX - Free Report) , Avient Corporation (AVNT - Free Report) and Innospec Inc. (IOSP - Free Report) . TX currently carries a Zacks Rank #1 (Strong Buy), while AVNT and IOSP carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for TX’s current-year earnings stands at $6.54 per share, implying a 201.4% year-over-year increase. The consensus estimate for 2026 earnings for TX has been revised 14.5% higher over the past 60 days.

The Zacks Consensus Estimate for AVNT’s current-year earnings is pegged at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in all of the trailing four quarters, with the average surprise being 3.4%.

The Zacks Consensus Estimate for IOSP’s current-year earnings has moved up 3.9% over the past 60 days. Its earnings beat the Zacks Consensus Estimate in all of the trailing four quarters, with the average surprise being 12.9%.

Palantir Technologies Inc. (PLTR - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this company have returned +8.3% over the past month versus the Zacks S&P 500 composite's +0.6% change. The Zacks Internet - Software industry, to which Palantir Technologies belongs, has gained 12.7% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Palantir Technologies is expected to post earnings of $0.42 per share, indicating a change of +100% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $1.61 for the current fiscal year indicates a year-over-year change of +114.7%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $2.26 indicates a change of +40.2% from what Palantir Technologies is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Palantir Technologies.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Palantir Technologies, the consensus sales estimate for the current quarter of $2.17 billion indicates a year-over-year change of +84%. For the current and next fiscal years, $8.19 billion and $11.67 billion estimates indicate +83% and +42.5% changes, respectively.

Last Reported Results and Surprise HistoryPalantir Technologies reported revenues of $1.94 billion in the last reported quarter, representing a year-over-year change of +92.8%. EPS of $0.41 for the same period compares with $0.16 a year ago.

Compared to the Zacks Consensus Estimate of $1.81 billion, the reported revenues represent a surprise of +7.16%. The EPS surprise was +17.14%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Palantir Technologies is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Palantir Technologies. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term.

MassMutual Private Wealth & Trust FSB increased its position in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 29.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,720 shares of the semiconductor manufacturer’s stock after purchasing an additional 1,314 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Micron Technology were worth $6,092,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in MU. Andar Capital Management HK Ltd lifted its position in shares of Micron Technology by 856,960.3% during the second quarter. Andar Capital Management HK Ltd now owns 34,282,413 shares of the semiconductor manufacturer’s stock worth $39,571,847,000 after purchasing an additional 34,278,413 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Micron Technology in the second quarter worth about $22,182,263,000. Bank of America Corp DE grew its holdings in shares of Micron Technology by 26.6% in the second quarter. Bank of America Corp DE now owns 10,174,757 shares of the semiconductor manufacturer’s stock worth $11,744,621,000 after purchasing an additional 2,136,470 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Micron Technology in the second quarter worth about $8,402,393,000. Finally, Wellington Management Group LLP increased its stake in Micron Technology by 28.7% in the 2nd quarter. Wellington Management Group LLP now owns 5,045,141 shares of the semiconductor manufacturer’s stock worth $5,823,556,000 after buying an additional 1,125,414 shares during the period. 80.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on the stock. Barclays boosted their price objective on shares of Micron Technology from $1,175.00 to $2,000.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. Raymond James Financial reaffirmed an “outperform” rating on shares of Micron Technology in a research note on Thursday. UBS Group reiterated a “buy” rating and issued a $1,625.00 price target (up from $535.00) on shares of Micron Technology in a report on Wednesday, September 23rd. KeyCorp reissued an “overweight” rating on shares of Micron Technology in a research note on Thursday. Finally, BNP Paribas Exane lifted their target price on Micron Technology from $615.00 to $1,700.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Forty-one investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,385.93.

Check Out Our Latest Stock Report on Micron Technology Insider Activity at Micron Technology In other Micron Technology news, CEO Sanjay Mehrotra sold 40,000 shares of Micron Technology stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $968.90, for a total value of $38,756,000.00. Following the transaction, the chief executive officer owned 264,503 shares in the company, valued at $256,276,956.70. The trade was a 13.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Scott Allen sold 879 shares of the stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $1,000.00, for a total transaction of $879,000.00. Following the sale, the chief accounting officer directly owned 34,958 shares of the company’s stock, valued at approximately $34,958,000. The trade was a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,879 shares of company stock valued at $90,939,466 over the last quarter. 0.24% of the stock is owned by corporate insiders.

Micron Technology Stock Performance Shares of MU stock opened at $1,074.89 on Monday. The firm has a market cap of $1.21 trillion, a price-to-earnings ratio of 14.48, a PEG ratio of 0.20 and a beta of 2.22. The company’s 50 day moving average is $957.97 and its 200 day moving average is $823.35. The company has a quick ratio of 2.94, a current ratio of 3.31 and a debt-to-equity ratio of 0.03. Micron Technology, Inc. has a 52-week low of $179.61 and a 52-week high of $1,255.00.

Micron Technology (NASDAQ:MU – Get Free Report) last posted its earnings results on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 earnings per share for the quarter, topping analysts’ consensus estimates of $31.77 by $1.65. The company had revenue of $54.23 billion during the quarter, compared to analyst estimates of $51.33 billion. Micron Technology had a return on equity of 92.62% and a net margin of 63.80%.Micron Technology’s revenue was up 379.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.03 earnings per share. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. On average, sell-side analysts anticipate that Micron Technology, Inc. will post 165.51 EPS for the current fiscal year.

Micron Technology Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 29th. Investors of record on Wednesday, October 14th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Wednesday, October 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.1%. Micron Technology’s dividend payout ratio (DPR) is presently 0.81%.

Micron Technology News Roundup Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron generated approximately $54.23 billion in quarterly revenue, up 379% year over year, and reported EPS of $33.42 versus the $31.77 consensus estimate. Management’s outlook calls for continued sequential growth in fiscal 2027, reinforcing confidence in the memory upcycle. Investors Had a Tepid Reaction to Micron’s Latest Earnings Report Positive Sentiment: AI data-center demand is driving strong demand for high-bandwidth memory and other advanced products. Long-term strategic customer agreements now cover more than 35% of revenue through 2030, with roughly $150 billion in potential revenue, improving visibility and reducing exposure to the traditional memory cycle. Micron: Memory Boom Still Has Legs Positive Sentiment: Micron’s unusually strong cash generation could soon translate into stock buybacks. Customer deposits, including billions already received under strategic agreements, and government incentives also help finance capacity expansion while limiting the amount shareholders must fund. Micron’s historic cash bonanza is set to rain down on investors Neutral Sentiment: Despite the rally, Micron still screens as inexpensive on reported earnings, with a trailing P/E near 14. Investors view its Nvidia collaboration, HBM4E development and capacity additions as potential support for growth through 2028 and beyond. Micron: The Trade Of The Decade Has Arrived Negative Sentiment: The principal risk is cyclicality: analysts expect growth to decelerate materially in later fiscal years, while additional DRAM or HBM supply, weaker pricing and higher interest rates could pressure margins. Some commentary argues the current earnings may reflect peak memory-cycle profits rather than a sustainable long-term baseline. Micron: The Memory Equity Cycle Is At Its Zenith Negative Sentiment: Investor Michael Burry’s bearish positioning on the AI sector adds a sentiment risk, with his outlook calling for significant declines in Micron and other AI-related stocks if the bubble deflates. Michael Burry Thinks the AI Bubble Will Burst Micron Technology Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, three-dimensional XPoint-related technologies, solid-state drives, and high-bandwidth memory products designed for demanding computing applications.

The company serves customers across the data center, artificial intelligence, networking, automotive, industrial, mobile, consumer electronics, and embedded markets.

See Also Five stocks we like better than Micron Technology Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam? The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Micron (MU - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this chipmaker have returned +5.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The Zacks Computer - Integrated Systems industry, to which Micron belongs, has gained 21% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Micron is expected to post earnings of $35.76 per share, indicating a change of +648.1% from the year-ago quarter. The Zacks Consensus Estimate has changed +2% over the last 30 days.

The consensus earnings estimate of $166.94 for the current fiscal year indicates a year-over-year change of +121.1%. This estimate has changed +4.7% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $189.94 indicates a change of +13.8% from what Micron is expected to report a year ago. Over the past month, the estimate has changed +0.4%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Micron.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Micron, the consensus sales estimate of $61.77 billion for the current quarter points to a year-over-year change of +352.8%. The $262.94 billion and $320 billion estimates for the current and next fiscal years indicate changes of +97.4% and +21.7%, respectively.

Last Reported Results and Surprise HistoryMicron reported revenues of $54.23 billion in the last reported quarter, representing a year-over-year change of +379.3%. EPS of $33.42 for the same period compares with $3.03 a year ago.

Compared to the Zacks Consensus Estimate of $51 billion, the reported revenues represent a surprise of +6.32%. The EPS surprise was +5.73%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Micron is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Micron. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits , /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.

Heart failure can worsen long before symptoms become noticeable. Pulmonary artery pressure — the pressure of blood flowing from the heart to the lungs — can rise as heart failure worsens, often weeks before patients experience any symptoms. The CardioMEMS HF System, which has been shown to reduce heart failure hospitalizations2,3 and mortality risk4,5, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery. For more than a decade, clinicians have used pulmonary artery pressure readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment.

Building on that clinical experience with CardioMEMS, Abbott is continuing to evolve heart failure management with digital tools that help keep clinicians and patients connected between office visits. The CardioMEMS HF System with the CardioGuide HF App represents an important step toward helping patients take an earlier, more active role in understanding and managing their heart failure.

"Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients access to their pressure trends and personalized guidance from their care team, the CardioGuide HF App can help patients better understand their condition, understand why treatment adjustments are recommended, and take a more active role in managing their heart failure."

The new CardioMEMS HF System capabilities also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. Once in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App, ensuring patients receive timely feedback and guidance from their care team.

"Abbott is reshaping heart failure care by bringing meaningful, actionable information directly to patients," said Katie Spayde, vice president of Abbott's heart failure division. "For many people living with heart failure, managing their condition is part of everyday life. By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits."

Abbott plans to make CardioGuide HF App and Dynamic Treatment Plan available later this year.

Frequently Asked Questions

What is heart failure?
Heart failure is a chronic, progressive condition in which the heart is unable to pump enough blood to meet the body's needs. It can cause shortness of breath, fatigue and swelling, and tends to worsen over time. Heart failure affects millions of people worldwide and is a leading cause of hospitalization.

What is pulmonary artery pressure, and why does it matter in heart failure?
Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. Rising pulmonary artery pressure is one of the earliest signs of worsening heart failure, often before a patient feels any symptoms. Monitoring pulmonary artery pressure remotely helps clinicians detect these changes early and adjust treatment before hospitalization is needed.

What is the CardioGuide HF App?
The CardioGuide HF App is a mobile app for people living with heart failure who have a CardioMEMS pulmonary artery pressure sensor. The app displays a patient's own pulmonary artery pressure readings and trends on their iOS or Android smartphone.

How does the CardioGuide HF App work with the CardioMEMS HF System?
The CardioMEMS HF System includes an implanted pulmonary artery pressure sensor, the CardioMEMS HERO device and the Merlin.net Patient Care Network Portal.

Individuals implanted with a CardioMEMS sensor can use the CardioMEMS HERO device to take pressure readings, which are transmitted to their care team through the Merlin.net Patient Care Network Portal. The CardioGuide HF App complements the system by giving patients direct visibility into their pulmonary artery pressure readings and trends on their smartphones.

Together, the CardioMEMS HF System and CardioGuide HF App help keep both clinicians and patients informed and engaged in heart failure management.

What is the Dynamic Treatment Plan?
Dynamic Treatment Plan (DTP) is a feature available through Abbott's Merlin.net Patient Care Network Portal that enables care teams to communicate treatment plan updates directly to CardioMEMS patients through the CardioGuide HF App. When enabled by a clinician, patients can receive updates related to their individual heart failure management plan through the CardioGuide HF App.

About the CardioMEMS HF System
Abbott's CardioMEMS HF System is the leading remote hemodynamic monitoring platform for heart failure patients. The system features a small pressure-sensing device implanted permanently in the pulmonary artery. The device allows clinicians to remotely monitor pulmonary artery pressure through the Merlin.net Patient Care Network Portal and proactively adjust treatment before hospitalization is needed. Supported by more than a decade of clinical evidence, CardioMEMS is the most-studied1 and only FDA-approved wireless heart failure monitoring system proven to reduce heart failure hospitalizations2,3 and mortality risk4,5. Additional information about the CardioMEMS HF System is available here.

Indications and Important Safety Information
For U.S. important safety information on the CardioMEMS HF System, visit: Indications, Safety and Warnings for the CardioMEMS HF System.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube. 

1Abbott. Data on file.
2Heywood JT, Zalawadiya S, Bourge RC, et al. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. J Card Fail. 2023;29(1):56–66. doi: 10.1016/j.cardfail.2022.10.422.
3Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circ Heart Fail. 2016;9(6):e002600. doi:10.1161/CIRCHEARTFAILURE.115.002600.
4Lindenfeld J, Costanzo MR, Zile MR, et al., on behalf of the GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Meta-Analysis of Implantable Hemodynamic Monitors for HFrEF. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2024;83:682-694. doi:10.1016/j.jacc.2023.11.030.
5Zalawadiya S, Abraham J, Rathman L, et al. Early reduction of pulmonary artery pressures is associated with improved mortality among Medicare beneficiaries with heart failure. JACC Heart Fail. 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589.

SOURCE Abbott

Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis

Exploratory biomarker analysis provides deeper insights on the immunometabolic biology of psoriasis and potential impact of Taltz (ixekizumab) and Zepbound (tirzepatide) vs. Taltz alone in the TOGETHER-PsO study in adults with psoriasis and obesity

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference taking place Oct. 8-11 in Las Vegas. Twenty-one poster presentations provide insights spanning disease control, treatment experience and outcomes across patient populations, demonstrating Lilly's commitment to addressing the everyday burden of chronic dermatologic diseases such as atopic dermatitis, psoriasis and alopecia areata. Key data presentations include EBGLYSS (lebrikizumab-lbkz) for the treatment of moderate-to-severe atopic dermatitis and the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) in psoriasis and obesity or overweight.

"For people living with chronic skin conditions, such as atopic dermatitis and psoriasis, the burden can be constant—relentless itch and significant pain that get in the way of daily routines," said Adrienne Brown, executive vice president and president, Lilly Immunology. "The breadth of dermatologic data we're presenting at Fall Clinical highlights our continued focus on addressing the needs of people living with immune and inflammatory conditions and advancing outcomes that matter most to them."

New data on EBGLYSS will be presented with 13 poster presentations exploring a range of topics important to atopic dermatitis care, including durable disease control, less frequent maintenance dosing in adolescents and less topical treatment use. Data will also include investigational efficacy and safety findings for EBGLYSS in pediatric patients as young as six months, as well as findings in patients whose disease affects high-impact areas such as the hands and feet.

Six presentations on Taltz and Zepbound used concomitantly offer new insights on immunometabolic health at the intersection of psoriasis and obesity. These data include an exploratory biomarker analysis from the TOGETHER-PsO study of adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one weight-related comorbid condition—helping advance the understanding of the potential interconnected biology between these two chronic conditions.

Additionally, long-term durable outcomes with Olumiant (baricitinib) in pediatric patients 12 years of age and older with severe alopecia areata will be presented from the BRAVE-AA-PEDS clinical trial, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata.

Key Lilly Presentations at Fall Clinical 2026
Presentations will be available at www.lilly.com.

Abstract Title

Lead Author

EBGLYSS: Stable and durable disease control

Lebrikizumab dosed every 8 weeks as
maintenance provides durable response in
adolescent patients with moderate-to-severe
atopic dermatitis

Vikash Oza

Stable disease control and reduced flare rates
with lebrikizumab in adolescents with
moderate-to-severe atopic dermatitis

Vikash Oza

Lebrikizumab provides clinically meaningful
response in adults and adolescents with
moderate-to-severe atopic dermatitis:
ADhope 1 study primary results 

Diamant Thaçi

EBGLYSS: Real-World Evidence

Real-world treatment persistence of
lebrikizumab by atopic comorbidity among
patients with moderate-to-severe atopic
dermatitis in the US

Shawn Kwatra

Asthma control in patients with moderate-to-
severe atopic dermatitis and comorbid
asthma receiving lebrikizumab in a real-world
setting: Interim data from the ADlife non-
interventional study

Roland Buhl

Real-world disease burden and treatment
patterns in patients with atopic dermatitis
and limited skin involvement who meet
criteria for advanced systemic therapy in the
US and Canada

Amy Paller

Lebrikizumab impact on alleviating disease
severity, itch burden and quality of life in
patients with moderate-to-severe atopic
dermatitis (AD): 16-week interim results from
a European prospective observational study
(ADtrust)

Jan Gutermuth

EBGLYSS: High Impact Areas and High Disease Burden

Lebrikizumab is effective in patients with
atopic hand and foot dermatitis: 16-week
results from the randomized, double-blind,
placebo-controlled ADtouch trial

Jonathan Silverberg

Lebrikizumab provides clinically meaningful
response in face and hands in adults and
adolescents with moderate-to-severe atopic
dermatitis: ADhope 1 study

Christian Vestergaard

Lebrikizumab shows efficacy in patients with
moderate-to-severe atopic dermatitis,
including patients with predominantly
moderate disease (ADhope 1)

Mónica Munera-Campos

EBGLYSS: Efficacy and Safety in Pediatrics

Lebrikizumab for pediatric patients aged ≥6
months with moderate-to-severe
AD: Phase 3 ADorable-1 week-16 results

Lawrence F. Eichenfield

Lebrikizumab improves itch and sleep in
pediatric patients with moderate-to-severe
atopic dermatitis: Results from the Phase 3
ADorable-1 Study

Lawrence F. Eichenfield

Lebrikizumab safety in pediatric patients with
moderate-to-severe atopic dermatitis:
Results from the randomized, double-blind,
placebo-controlled, Phase 3 study ADorable-1
through Week 16

Lawrence F. Eichenfield

Taltz + Zepbound: TOGETHER Program on Concomitant Use for Psoriatic Disease and
Obesity 

Uncovering the potential immunometabolic
impact of tirzepatide added to ixekizumab in
patients with psoriasis and overweight or
obesity: Biomarker insights from TOGETHER-
PsO

James G. Krueger

Ixekizumab with tirzepatide was associated
with reduced CV risk factors and calculated 
CV risk beyond ixekizumab alone in psoriatic
disease and obesity

Brittany Weber

Real-world patient experiences with
concomitant ixekizumab and tirzepatide in
psoriasis: Participants recruited from the
Zepbound Savings for Taltz US Customer
Support Program

April Armstrong

Cost-effectiveness of treating psoriasis
patients with obesity/overweight with
ixekizumab plus tirzepatide versus
ixekizumab alone

Joseph F. Merola

Concomitant treatment with ixekizumab and
tirzepatide according to demographics and
disease characteristics for patients with
psoriasis and overweight or obesity:
Subgroup analyses from the TOGETHER-PsO
randomized trial

Andreas Pinter

Benefits of concomitant treatment with
ixekizumab and tirzepatide for patients with
psoriatic disease and overweight/obesity: An
overview of results from the TOGETHER trials

Joseph F. Merola

Olumiant: Efficacy and Safety in Pediatrics

Long-term safety of baricitinib in pediatric
patients with atopic dermatitis aged 2 to <18
years with up to 5.2 years of exposure

Andreas Wollenberg

Baricitinib provides sustained efficacy
through 1.5 years and consistent safety up to
a maximum of 2.5 years of treatment in
adolescents with severe alopecia areata:
BRAVE-AA-PEDS trial results

Brittany Craiglow

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe.

Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication.

Olumiant is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly. 

About EBGLYSS (lebrikizumab-lbkz)
EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.1,2,3 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of atopic dermatitis, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.1

The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating more than 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin) and adolescent open-label (ADore) studies. The program also includes a study assessing the impact of EBGLYSS on vaccine immune response in adults (ADopt-VA). EBGLYSS has been studied in patients with skin of color (ADmirable) and in dupilumab-experienced patients (ADapt).

EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment, administered with or without topical corticosteroids, that offers every-four-week (EU and U.S.) or every-eight-week maintenance dosing (U.S.) for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription therapies.1  In the U.S., the recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is 250 mg every four weeks or every eight weeks.1

About Taltz (ixekizumab)
Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. Taltz is approved to treat adults with active psoriatic arthritis and adults and children 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, Taltz is approved for adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity.

About Olumiant (baricitinib) 
Olumiant, a once-daily, oral JAK inhibitor, was discovered by Incyte and licensed to Lilly. Baricitinib is approved in the U.S. and more than 75 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Olumiant is also approved for adults and pediatric patients 12 years of age and older with severe AA in the U.S., European Union and Japan. Olumiant is also approved for the treatment of hospitalized adults with COVID-19 in the U.S.

The U.S. FDA-approved labeling for Olumiant includes a Boxed Warning for Serious Infections, Mortality, Malignancy, Major Adverse Cardiovascular Events and Thrombosis. See the full Prescribing Information here.4

In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of Olumiant and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

EBGLYSS INDICATION AND SAFETY SUMMARY
EBGLYSS® (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids. 

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

Before using
Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

Have a parasitic (helminth) infection. Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS. Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Possible side effects
EBGLYSS can cause serious side effects, including:

Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing swelling of the face, lips, mouth, tongue or throat hives itching fainting, dizziness, feeling lightheaded skin rash cramps in your stomach area (abdomen) Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. The most common side effects of EBGLYSS include:

eye and eyelid inflammation, including redness, swelling, and itching injection site reactions shingles (herpes zoster) These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How to take

See the detailed "Instructions for Use" that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes. Use EBGLYSS exactly as prescribed by your healthcare provider. EBGLYSS is given as an injection under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver. If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. Learn more
EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com.

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.

LK CON BS AD APP
EBGLYSS®, its delivery device base, and Lilly Support Services™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

TALTZ INDICATIONS AND SAFETY SUMMARY
Taltz® (tȯl-ts) is an injectable medicine used to treat:

People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Adults with active psoriatic arthritis. Adults with active ankylosing spondylitis. Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. It is not known if Taltz is safe and effective in children for conditions other than plaque psoriasis or in children under 6 years of age.

Warnings - Taltz affects the immune system. It may increase your risk of infections, some people have had serious infections, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away.

Your doctor should check you for TB before you start Taltz, and watch you closely for signs of TB during and after treatment with Taltz. If you have TB, or had it in the past, your doctor may treat you for it before you start Taltz.

Do not use Taltz if you have had a serious allergic reaction to ixekizumab or any other ingredient in Taltz, such as: swelling of your eyelids, lips, mouth, tongue or throat, trouble breathing, feeling faint, throat or chest tightness, or skin rash. Get emergency help right away if you have any of these reactions. See the Medication Guide that comes with Taltz for a list of ingredients.

Severe skin reactions that look like eczema can happen during treatment with Taltz from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with Taltz if you develop severe skin reactions. Tell your doctor if you have any of the following: redness or rash, itching, patches, your skin is dry or feels like leather, blisters or abrasions that ooze or become crusty, small bumps or plaques with scale or crusting.

Crohn's disease or ulcerative colitis (inflammatory bowel disease) can start or get worse with Taltz use. Tell your doctor if you have any of these symptoms or if they get worse: stomach pain, diarrhea, and weight loss.

You should not get live vaccines while taking Taltz. You should get the vaccines you need before you start Taltz.

Common side effects
The most common side effects of Taltz include:

Injection site reactions Nausea Upper respiratory infections Fungal skin infections Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using
Before you use Taltz, review these questions with your doctor:

Are you being treated for an infection? Do you have an infection that does not go away or keeps coming back? Do you have TB or have you been in close contact with someone with TB? Do you have possible symptoms of an infection such as fever, cough, sores, diarrhea, or other symptoms? Ask your doctor about other possible symptoms. Do you have Crohn's disease or ulcerative colitis?
Tell your doctor if:

You need any vaccines or have had one recently. You take prescription or over-the-counter medicines, vitamins, or herbal supplements. You are pregnant or planning to become pregnant. It is not known if Taltz can harm an unborn baby. Pregnancy Exposure Registry: There is a pregnancy registry to collect information about women who are exposed to Taltz during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking Taltz, you are encouraged to enroll in the pregnancy registry by calling 1-800-284-1695 or by visiting online at http://www.pregnancyregistry.lilly.com. You are breastfeeding or planning to breastfeed. It is not known if Taltz passes into breastmilk. How to take
See the instructions for use that come with Taltz. There you will find information about how to store, prepare, and inject Taltz. Adults may self-inject after receiving training from a healthcare provider.

For children 6 to 17 years of age:

If your child's healthcare provider decides that you may give Taltz injections at home, you should receive training on the right way to prepare and inject Taltz. Do not try to give Taltz to your child until you have been shown how to inject Taltz. Children should not inject themselves with Taltz. You or an adult caregiver should prepare and give Taltz injections to your child. Learn more
Taltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to taltz.lilly.com.

This summary provides basic information about Taltz but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Taltz and how to take it. Your doctor is the best person to help you decide if Taltz is right for you.

IX CON BS 20AUG2024

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed.  You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. 

Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

OLUMIANT INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Olumiant® (O-loo-me¯ -ant) is a Janus kinase (JAK) inhibitor used to treat:

adults and adolescents 12 years and older with severe alopecia areata. adults with moderately to severely active rheumatoid arthritis after treatment with 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well enough or could not be tolerated. It is not known if Olumiant is safe and effective in children with juvenile idiopathic arthritis or with severe alopecia areata who are younger than 12 years old.

Warnings - Olumiant may cause serious side effects, including:

Serious infections, including tuberculosis (TB), shingles, and others caused by bacteria, fungi, or viruses. Some people have died from these infections. Olumiant can make you more likely to get infections or make any infections that you have worse. Your doctor should test for TB before starting Olumiant and watch for TB symptoms during treatment. You should not start Olumiant if you have any kind of infection unless your doctor tells you it is okay. While taking Olumiant, tell your doctor right away if you get symptoms of an infection, such as: fever, sweating, or chills muscle aches cough shortness of breath blood in phlegm weight loss warm, red, or painful skin or sores on your body diarrhea or stomach pain burning with urination or urinating more often than normal feeling tired If you get a serious infection, your doctor may stop Olumiant until your infection is controlled.

Increased risk of death in people 50 years of age or older who have at least 1 heart disease risk factor and are taking a medicine in a class of medicines called JAK inhibitors. Cancer and immune system problems. Olumiant may increase your risk of lymphoma and other cancers, including skin cancers. People taking a medicine in the class of medicines called JAK inhibitors have a higher risk of certain cancers, including lymphoma and lung cancer, especially if you are a current or past smoker. Follow your doctor's advice about having your skin checked for skin cancer while taking Olumiant. Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease risk factor and taking a medicine in the class of medicines called JAK inhibitors, especially if you are a current or past smoker. Get emergency help right away if you get any symptoms of a heart attack or stroke while taking Olumiant, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech Blood clots in the veins of your legs or lungs, and arteries. This may be life-threatening and cause death. Blood clots in the veins of legs and lungs have happened more often in people who are 50 years of age or older and with at least 1 heart disease risk factor taking a medicine in the class of medicines called JAK inhibitors. Stop taking Olumiant and tell your doctor or get emergency help right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden chest pain, or shortness of breath, while taking Olumiant. Allergic reactions. While taking Olumiant, if you have symptoms, such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, stop taking Olumiant and get emergency help right away. Some of these reactions seen in people taking Olumiant were serious. Tears in the stomach or intestines. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. While taking Olumiant, tell your doctor right away if you have fever and stomach-area pain that does not go away, and a change in bowel habits. Low blood sugar (hypoglycemia) in people with diabetes. Low blood sugar, including serious low blood sugar, has happened in people with diabetes after starting Olumiant and other JAK inhibitors. Your doctor may check your blood sugar more often. While taking Olumiant, tell your doctor if you have diabetes and you have signs or symptoms of low blood sugar. Changes in laboratory test results. Your doctor should do blood tests before and while taking Olumiant. You should not take Olumiant if your white or red blood cell count is too low or your liver tests are too high. Your doctor may pause your treatment with Olumiant because of changes in these test results. Your doctor should also check your cholesterol levels approximately 12 weeks after you start Olumiant and as needed. Common side effects
The most common side effects of Olumiant in people treated for alopecia areata include:

upper respiratory tract infections (cold or sinus infections) headache acne increased cholesterol levels increased muscle enzyme levels urinary tract infection increased liver enzyme levels inflammation of hair follicles (folliculitis) tiredness lower respiratory tract infections nausea genital yeast infection low red blood cell count (anemia) low white blood cell count (neutropenia) stomach-area (abdominal) pain shingles (herpes zoster) increased weight The most common side effects of Olumiant in people treated for rheumatoid arthritis include:

upper respiratory tract infections (cold or sinus infections) nausea herpes simplex virus infections, including cold sores shingles (herpes zoster) These are not all the possible side effects of Olumiant. Tell your doctor if you have any side effects. You can report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using
Before you use Olumiant, tell your doctor if you:

❑ Are being treated for an infection, have an infection that won't go away or keeps coming back, or think you have symptoms of an infection.
❑ Have TB or have been in close contact with someone with TB.
❑ Have or had shingles (herpes zoster).
❑ Have or had hepatitis B or C, cancer, or blood clots in the veins of your legs or lungs.
❑ Live, have lived, or have visited parts of the country that increase your risk of fungal infections. These may include the Ohio and Mississippi River valleys and the Southwest. Ask your doctor if you do not know if you have lived in an area where these infections are common.
❑ Are a current or past smoker.
❑ Have or had a heart attack, other heart problems or stroke.
❑ Have other medical conditions, including kidney or liver problems, low blood cell counts, diabetes, lung disease, HIV, or a weak immune system.
❑ Have any stomach-area pain or have been diagnosed with inflammation in the large intestine (diverticulitis) or ulcers in your stomach or intestines.
❑ Have recently received or plan to receive a vaccine. People taking Olumiant should not receive live vaccines.
❑ Are pregnant or plan to become pregnant. It is not known if Olumiant may harm your unborn baby. There is a pregnancy exposure registry that monitors women exposed to Olumiant during pregnancy. If you become pregnant during treatment with Olumiant call 1‑800‑284-1695 or visit https://pregnancyregistry.lilly.com to report the pregnancy.
❑ Are breastfeeding or plan to breastfeed. You should not breastfeed while taking Olumiant and for 4 days after the last dose. Talk to your doctor about the best way to feed your baby while taking Olumiant.
❑ Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. It is especially important to tell your doctor, if you take:

a medicine called probenecid. medicines that affect your immune system, such as biologic medications, other JAK inhibitors, or strong immunosuppressants (such as azathioprine or cyclosporine) since these may increase your risk of infection. ❑ Are under age 18. It is not known if Olumiant is safe and effective in children for conditions other than alopecia areata or in children under 12 years of age.

How to take

Take Olumiant exactly as your doctor says. Take Olumiant once a day by mouth with or without food. Talk to your doctor if you cannot swallow tablets whole. If you take too much Olumiant, call your doctor or poison control center at 1‑800‑222‑1222, or go to the nearest hospital emergency room right away. Learn more
Olumiant is a prescription medicine. For more information, call 1-800-545-5979 or go to www.olumiant.com.

This summary provides basic information about Olumiant but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Olumiant and how to take it. Your doctor is the best person to help you decide if Olumiant is right for you.

BA CON BS SEP2026

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to-severe atopic dermatitis and reflects Lilly's current beliefs and expectations. However, there can be no assurance that EBGLYSS will achieve Lilly's objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes and References
1 EBGLYSS. Prescribing Information. Lilly USA, LLC.
2 Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7
3 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024
4 Olumiant. Prescribing Information. Lilly USA, LLC.

SOURCE Eli Lilly and Company

Broadcom (AVGO +0.82%) trades at $352 as of Oct. 2, 2026, so $2,000 buys roughly 5.7 shares. I see a realistic path for the stock to double, and possibly do a bit better, turning that stake into $5,000 by 2030.

It assumes demand for artificial intelligence chips and networking will keep growing, without a supply shock or a stall in data center spending. Broadcom's own outlook still points to a high-growth stretch that could lift the shares.

Image source: Getty Images.

CEO Hock Tan says Broadcom could exceed $30 in earnings per share in fiscal 2028 The insatiable demand for AI chips strengthens the case that this stock offers substantial upside over the next few years.

Broadcom designs custom accelerators, or XPUs, as well as the networking components and infrastructure software that move data across AI workloads. In the fiscal third quarter ended in August, AI semiconductor revenue grew 221% year over year.

Hyperscalers have accelerated data-center spending, yet they are still short on compute. Alphabet (Google) said it will "increase significantly" its capital spending in 2027. Amazon is in a similar position and expects to remain supply-constrained next year. This points to growing demand for Broadcom.

The company expects AI revenue to reach $230 billion in fiscal 2028, up from an expected $58 billion this year. During the fiscal Q3 2026 earnings call, CEO Hock Tan said, "We are very much on target to exceed $30 in earnings per share in fiscal 2028."

Premium Feature

Moneyball Superscore

91/100

Today's Change

(

0.82

%) $

2.91

Current Price

$

358.05

How $2,000 turns into $5,000 The stock trades at just 11.7 times fiscal 2028 estimates. Assuming Broadcom hits the fiscal 2028 earnings target, a price of about $700 implies a multiple in the low 20s, roughly twice today's multiple on those estimates, and still well within Broadcom's historical valuation range. That would turn $2,000 into about $4,000.

The rest of the path is further earnings growth. If earnings reach $40 by fiscal 2030, which is only a modest increase over fiscal 2028, a similar multiple could push the stock to around $900, turning today's $2,000 into about $5,000.

Supporting the case for further growth, Tan said on the Sept. 2, 2026, earnings call that management expects demand to grow through 2029 for future generations of custom chips being developed with Google. Broadcom is also designing chips for Anthropic, OpenAI, and Meta Platforms.

The supply chain is still a risk. Broadcom says it has secured the components to meet its outlook through fiscal 2028, but a geopolitical shock or an industry downturn could still send the stock down.

Even so, the long-term trend toward more complex chip designs and demand in the AI market is a bullish setup for Broadcom. The cost and power efficiency of custom chips may erode the market share of traditional chips, including Nvidia's.

Tan said the chip designed for OpenAI can run frontier models at half the cost of a GPU. That shift is a long-term tailwind, and it raises the odds of market-beating gains.

Coinbase has long been pitched as the smart, stable way to ride crypto without holding it directly, but the numbers behind that pitch tell a very different story about which bet actually holds its value.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Over the last year, Coinbase (NASDAQ: COIN | COIN Price Prediction) has seen its shares fall by 51%. In contrast, Bitcoin (CRYPTO: BTC) has fallen 30%. This difference prompts a deeper look into the Coinbase stock versus Bitcoin debate. Many investors often view Coinbase as a more stable option for gaining exposure to cryptocurrency, particularly for retirement accounts.

As of October 2, 2026, Coinbase shares were priced at $183, while Bitcoin was trading around $86,189 as of October 5. So which investment has proven better for owning crypto, and which is more suitable for long-term investing?

Coinbase Shares Lag Behind Bitcoin Over One Year and Five

The gap in performance is significant. Over the past year, Coinbase’s stock lost 51%, whereas Bitcoin declined by 30%. This means that an investor who put $10,000 into each a year ago would now have approximately $4,900 in Coinbase shares and about $7,000 in Bitcoin.

A longer timeframe reveals an even bleaker picture for Coinbase. Over the past five years, its shares have fallen 21%, and they have fallen 19% so far in 2026. Meanwhile, Bitcoin’s value rose from around $51,500 in early October 2021, up about 67%, even after a recent 32% drop from its peak of $126,080.

Short-term numbers align with this trend. Over the last month, Coinbase shares increased by 4.6%, while Bitcoin gained about 6%. However, over the past week, Coinbase stock fell 6.2%, including a 3.3% drop on October 2, while Bitcoin rose 3.6%.

Business Risks Make Coinbase Stock More Volatile Than Bitcoin

When you hold Bitcoin, you own a single asset whose price fluctuates. In contrast, owning Coinbase stock means you’re investing in a business. Coinbase’s revenue depends on how much customers trade—trading activity correlates with crypto price movements. Additionally, Coinbase faces various challenges such as operational costs, fierce competition, and regulatory scrutiny that Bitcoin does not.

These extra complexities help explain why Coinbase’s stock can decline more sharply. When cryptocurrency prices fall, trading activity typically declines, reducing Coinbase’s revenue. The stock may also suffer even if Bitcoin’s price is stable. Furthermore, neither Coinbase nor Bitcoin pays dividends, meaning they don’t generate regular income for investors.

That said, Coinbase can also benefit from conditions that Bitcoin cannot. During a strong crypto market rally, increased trading volume can boost Coinbase’s earnings significantly, sometimes leading its stock to rise faster than Bitcoin’s price.

Spot Bitcoin ETFs Challenge Coinbase’s Retirement Account Advantage

Historically, one of the main benefits of investing in Coinbase was the convenience it offered. Investors could include its shares in an IRA or brokerage account, while owning Bitcoin directly required a self-custody wallet or a custodian service.

However, the introduction of spot Bitcoin ETFs has changed this landscape. These funds hold Bitcoin and trade like regular stocks, allowing retirement savers to gain exposure to Bitcoin within the same accounts that can hold Coinbase shares. Additionally, states such as Indiana are now adding crypto options to public retirement plans. In fact, Coinbase acts as a custodian for many of these funds, earning fees in both scenarios.

Is Coinbase Stock or Bitcoin the Better Way to Own Crypto? Given the current performance, Bitcoin appears to be the better option for owning cryptocurrency. It has lost less over the past year, has gained value over the last five years, and carries no associated business risks, while Coinbase stock has declined. For those investing in retirement accounts, a spot Bitcoin ETF now offers the benefits of Bitcoin without the custody complications that made Coinbase appealing in the past.

This conclusion challenges the perception that Coinbase is the safer investment route, as its stock has shown larger swings in value both up and down. The outcome could change if Coinbase outperforms Bitcoin during a future crypto market rally, potentially showcasing how the business can add returns beyond simply holding the coin. Until then, will the Coinbase stock versus Bitcoin conversation continue to favor Bitcoin?

Contact [email protected] for any questions or corrections.

Cameco (CCJ +0.50%) stock has fallen below $90, closing at $85.69 on Oct. 1. That's a significant retreat for a stock that has traded as high as $135.24 over the past year. But the underlying nuclear story hasn't changed nearly as much as Cameco's stock price, which makes it worth a closer look at these levels.

Uranium demand remains strong One thing you have to understand about Cameco is that it isn't simply a bet on uranium prices. Yes, it is one of the world's largest uranium producers, but it also operates nuclear fuel service businesses and owns 49% of Westinghouse, giving it exposure to everything from uranium mining to nuclear reactor servicing. That said, tight uranium supplies continue to give the company a strategic advantage.

Uranium-market consultancy UxC estimates that utilities have approximately 3.1 billion pounds of uncovered uranium requirements through 2045. Over the past five years, roughly 815 million pounds of uranium equivalent were consumed by reactors, while only about 589 million pounds were placed under long-term contracts. That gap could create plenty of opportunities for an established producer like Cameco.

Image source: Getty Images.

The company already has contracts covering average annual deliveries of more than 28 million pounds of uranium over the next five years. Earlier this year, Cameco also signed a nine-year agreement to supply India with nearly 22 million pounds of uranium, a contract valued at approximately $2.6 billion at the time of announcement.

Today's Change

(

0.50

%) $

0.43

Current Price

$

85.61

The numbers aren't perfect Cameco's latest results do help explain some of the recent weakness. Q2 adjusted EBITDA came in at roughly $279 million, while adjusted net earnings clocked in at around $55 million.

Both were lower than a year earlier, primarily due to lower earnings from Westinghouse, while lower planned uranium sales volumes also weighed on results.

There have also been operational headaches. Flooding in northern Saskatchewan disrupted Cameco's primary supply route to its McArthur River and Key Lake operations, while its Cigar Lake uranium mine temporarily suspended production for about two weeks following problems at Orano Group's McClean Lake mill. Cameco still maintained its 2026 uranium production guidance of 19.5 million to 21.5 million pounds attributable to the company. And the balance sheet remains solid. Cameco finished June with roughly $784 million in cash against $713 million in debt, plus another $713 million available through an undrawn revolving credit facility.

The biggest concern here is valuation. Even after falling below $90, Cameco stock isn't exactly cheap. You're still paying a premium for its exposure to rising nuclear demand, uranium supply constraints, and Westinghouse.

But Cameco also has something many nuclear stocks don't: large-scale uranium production and substantial existing revenue. It owns stakes in some of the world's highest-quality uranium assets, has long-term contracts in place, and maintains exposure to higher uranium prices as it signs new contracts. The company recently increased its ownership of Cigar Lake to 57.4%, too, further concentrating its portfolio around one of the world's most important uranium mines.

So the stock dropping below $90 doesn't eliminate the valuation risk. But if you believe nuclear power will continue expanding over the next decade, this pullback does provide a considerably cheaper entry point into one of the industry's most established companies.

New offering leverages EPAM's decades of enterprise engineering depth and established AI lab partnerships to supply advanced data and evaluation services

, /PRNewswire/ -- EPAM Systems, Inc. (NYSE: EPAM) today announced the launch of a new strategic offering dedicated to powering the next generation of frontier AI models. Positioned as a foundational intelligence layer for the AI ecosystem, EPAM's services address a critical industry bottleneck: enabling frontier AI models to execute complex, specialized enterprise workflows more reliably.

EPAM Unveils New Frontier AI Service, Bridging the Enterprise Intelligence Gap for GenAI and Autonomous Agents While early generative AI models were trained on broad, publicly available data to master general language and coding, the industry has entered a new era. As adoption accelerates, the focus has shifted toward complex enterprise workflows, multi-step agentic execution and specialized vertical reasoning that require vetted domain knowledge. By leveraging its deep, multi-decade experience in designing, integrating and maintaining complex enterprise workflows, EPAM will offer specialized competencies in high-fidelity data generation, rigorous model evaluation and the creation of custom reinforcement learning (RL) environments.

Read our perspective on the future of model training and how EPAM is partnering with leading labs to solve the enterprise intelligence gap.

"As frontier AI shifts from general experimentation to complex enterprise workflows, the demand has fundamentally moved from raw compute to specialized domain intelligence," said Elaina Shekhter, Chief Strategy & Transformation Officer at EPAM. "Our new offering bridges that critical gap by pairing our decades of deep engineering heritage with our established Frontier AI partnerships, uniquely positioning us to capture this massive, high-value market. We aren't just participating in the GenAI wave, we're actively building infrastructure that makes enterprise-grade autonomy possible."

These capabilities are further anchored by EPAM's established partnerships with the leading frontier AI labs, including Anthropic, OpenAI, Google and Microsoft. With one of the largest AI engineering initiatives in the industry, EPAM has trained and invested in nearly 10,000 Claude-certified architects, 3,000+ OpenAI-certified forward-deployed engineers (FDEs), and 5,000+ Gemini-certified specialists to-date. This certified proficiency across major model ecosystems, combined with firsthand insight into where models succeed and struggle in enterprise deployments, provides labs with the trusted, high-caliber collaboration required to accelerate model development and drive enterprises from pilot to measurable business outcomes.

A cornerstone of the service is the development of RL environments that support scenario simulation. These sophisticated, controlled virtual environments mirror complex enterprise systems and workflows, enabling developers to rigorously stress-test multi-turn interactions, reasoning and tool use before production while providing secure, closed-loop feedback for reinforcement learning and ongoing model improvement. According to research from Gartner® in its April 2026 report, titled Emerging Tech: AI Race: Simulation Supercharges Agent Evaluation and Self-Learning Loops for AI Agents, by 2028, 99% of agent platform providers will offer simulation environments, up from less than 25% in 2026.

Read our perspective on the future of model training and how EPAM is partnering with leading labs to solve the enterprise intelligence gap.

To learn more about EPAM's latest AI capabilities and enterprise engineering services, visit: www.epam.com/frontier-ai 

Source: Gartner Report, Emerging Tech: AI Race: Simulation Supercharges Agent Evaluation and Self-Learning Loops for AI Agents, By Radu Miclaus, Danielle Casey, etc., April 2026. Gartner is a trademark of Gartner, Inc. and/or its affiliates

About EPAM Systems
EPAM (NYSE: EPAM) is a global leader in AI transformation engineering and integrated consulting, serving Forbes Global 2000 companies and ambitious startups. With over thirty years of expertise in custom software, product and platform engineering, EPAM empowers organizations to become AI-Native enterprises, driving measurable value from innovation and digital investments. Recognized by industry benchmarks and leading analysts as a leader in AI, EPAM delivers globally while engaging locally, making the future real for clients, partners, and employees. 

We are proud to be recognized by Forbes, Glassdoor, Newsweek, Time Magazine, Great Place to Work and kununu as a Most Loved Workplace around the world. 

Learn more at www.epam.com and follow us on LinkedIn.

Forward-Looking Statements 
This press release includes estimates and statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Our estimates and forward-looking statements are mainly based on our current expectations and estimates of future events and trends, which affect or may affect our business and operations. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. Those future events and trends may relate to, among other things, developments relating to the war in Ukraine and escalation of the war in the surrounding region, political and civil unrest or military action in the geographies where we conduct business and operate, difficult conditions in global capital markets, foreign exchange markets, global trade, and the broader economy, the adoption and implementation of artificial intelligence technologies by EPAM and its clients, and the effect that these events may have on client demand and our revenues, operations, access to capital, and profitability. Other factors that could cause actual results to differ materially from those expressed or implied include general economic conditions, the risk factors discussed in the Company's most recent Annual Report on Form 10-K and the factors discussed in the Company's Quarterly Reports on Form 10-Q, particularly under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" and other filings with the Securities and Exchange Commission. Although we believe that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made based on information currently available to us. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

SOURCE EPAM Systems, Inc.

The media business getting ready to merge with Warner Bros. is Paramount Skydance Corp. (PSKY, Financials). Discovery launched a $52 billion debt issue, which increases the cost of closing the deal but provides funding for the acquisition.

Investment-grade and junk-rated bonds with interest rates as high as 9.1% that matured between 2028 and 2066 were included in the sale.

The cost of timing was high. According to the research, if Paramount had taken out a loan several months earlier, when Treasury rates were around one percentage point lower, it could have saved about $400 million a year in interest. Despite Paramount hedging some rate exposure, the deal was delayed due to a court dispute.

Despite this, there was a significant interest among investors. Apollo Global Management, Pimco, and hundreds of other organizations allegedly placed orders totaling over $150 billion.

Despite the scale of the funding, that demand demonstrates that Paramount could still tap deep credit markets. A larger interest cost that can limit future cash flow is the trade-off.

This makes integration even more crucial for shareholders. Because more money will be spent on debt payment, management will now have less leeway for poor profitability or postponed cost cuts.

The Warner Bros. merger's ability to produce sufficient profits and savings to support a financing package that is significantly more costly due to rising interest rates will be the next test.

Check the Warning Signs for

PSKY

now!

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced a collaboration with IBM and Red Hat to help organizations protect private applications during the period between vulnerability disclosure and patch deployment. The collaboration combines Zscaler Autonomous Application Shield, delivered through the Zscaler Zero Trust ExchangeTM security platform, with Lightwell from IBM and Red Hat to deliver adaptive, application-specific protection with validated software remediation in a single coordinated response.

The economics of exploitation have shifted. Capabilities that once required elite skills and weeks of manual effort are now widely available, and attackers are weaponizing newly disclosed vulnerabilities faster than enterprise patch cycles can respond. According to Mandiant's M-Trends 2026 report, the mean time to exploit a vulnerability has fallen below zero, meaning vulnerabilities are increasingly exploited before a public patch exists. Patching remains necessary, but on its own it can no longer keep pace. Organizations need protection that can be applied at machine speed while remediation is prepared and deployed.

This collaboration extends Zscaler's protection-first operating model for private applications, which assumes a remediation window will always exist and builds resilience around it: hide applications with Zscaler Private AccessTM (ZPATM) so they are harder to discover and target, segment access with Autonomous User-to-App Segmentation so a foothold does not become broad reachability, and shield reachable applications with Autonomous Application Shield so exploit attempts are stopped inline while the root cause is fixed. By uniting Zscaler Autonomous App Shield with Lightwell, the collaboration provides customers a coordinated path from immediate protection to durable fix.

Operating through the Zero Trust Exchange, Zscaler App Connectors continuously perform safe assessments of each private application's exposure points and vulnerabilities. The Zscaler cloud individually evaluates each application, ensuring only necessary protections are applied. When a new vulnerability emerges, adaptive protections can be applied inline and in real time, without waiting for a patch. Through this collaboration, Lightwell helps Zscaler defend its customers from potential cyber threats, with Zscaler blocking exploit attempts immediately at the network level. Lightwell then provides validated remediations for affected open source software, enabling customers to fix the underlying flaw at the source.

“As attackers weaponize newly disclosed vulnerabilities faster than enterprises can respond, organizations need a way to protect private applications immediately while fixes are being prepared and deployed,” said Joby Menon, Senior Vice President of Product Management at Zscaler. “Our collaboration with IBM and Red Hat brings together inline, application-specific protection and validated remediation to help customers reduce risk during that gap.”

Through this collaboration, Zscaler, IBM, and Red Hat will deliver integrated capabilities across the application security lifecycle, addressing critical needs including:

Exposure Discovery: Providing a current understanding of a private application's actual risk profile, updated as fast as applications change, rather than relying on periodic scans.Preemptive, Application-Specific Protection: Bridging the gap between vulnerability and patching. Applying only the protections a given application needs during the gap between disclosure and patching, reducing exposure while remediation is underway and avoiding one-size-fits-all policy noise.Machine-Speed Response: Deploying protections inline and in real time when a new vulnerability emerges, informed by global threat intelligence from across Zscaler's worldwide customer base.Validated Source-Level Remediation: Delivering tested software fixes through Lightwell so organizations can resolve the underlying vulnerability, with advisory and deployment support to prioritize and validate protections across complex environments. "AI is shrinking the window between vulnerability discovery and vulnerability exploitation. A window that was months or weeks is now hours and minutes,” said Gunnar Hellekson, vice president and general manager, Lightwell, Red Hat. “Lightwell helps keep open source safe by patching and fixing these vulnerabilities at machine speed. Collaborating with partners like Zscaler brings Lightwell’s capabilities to the forefront of enterprise networks, mitigating potential vulnerabilities head-on while patches are applied to critical systems."

Autonomous Application Shield is currently available through an Early Access Program. Availability, capabilities, and timing of the collaboration described herein are subject to change.

For a deeper dive into how Zscaler is helping protect against AI threats, please visit this blog.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. These forward-looking statements include the expected performance and benefits of Zscaler Autonomous Application Shield and its collaboration with IBM and Red Hat, including the delivery of adaptive, machine-speed protection for private applications. These forward-looking statements are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. A significant number of factors could cause actual results to differ materially from statements made in this press release, including those factors related to Zscaler's ability to achieve partner and customer adoption of Autonomous Application Shield and the collaboration described herein. Additional risks and uncertainties are set forth in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on September 3, 2026, which is available on our website at ir.zscaler.com and on the SEC's website at www.sec.gov. Any forward-looking statements in this release are based on the limited information currently available to Zscaler as of the date hereof, which is subject to change, and Zscaler will not necessarily update the information, even if new information becomes available in the future.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust ExchangeTM platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across 200+ public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contacts

Nick Gonzalez, Director of Public Relations, [email protected]

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in defense, national security, and global markets, today announced multiple contract awards totaling over $100 million to develop prototype mission applications and cyber capabilities providing space intelligence data in support of joint operations across the space and cyberspace domains.

Work under the contracts will provide warfighters with capabilities to collect and process complex radio frequency (RF) signals, develop intelligence on the operational environment and support the joint targeting cycle – the process used to identify, prioritize and target assets. The prototype systems will support electronic warfare and offensive cyber operations, including capabilities for access and battle damage assessment.

The work leverages the KnownSpace® Network, Kratos’ global RF collection infrastructure consisting of more than 190 strategically placed sensors around the world, along with RF data and capabilities provided by KnownSpace Recon+™, Kratos’ field-portable space domain awareness (SDA) terminals. In addition, the contracts will leverage Kratos’ software products, analytics and expertise in RF, signal processing, cybersecurity and software development, establishing a proven technology base that can be adapted and integrated to meet emerging space and cyber mission requirements.

“Kratos brings decades of space experience together with proven commercial technology and agile engineering to solve some of today’s most complex mission challenges,” said Greg Caicedo, Senior Vice President at Kratos. “Our systems, software and hardware support missions across SDA, command & control, satellite operations and cybersecurity. By building on proven technology and rapidly adapting it to emerging mission needs, we can deliver new capabilities faster and keep pace as the space environment changes.”

The Kratos KnownSpace family of SDA products and services which support these awards provide deep insights for global, sovereign, and tactical operations. Built on more than 30 years of satellite monitoring and RF expertise, the KnownSpace family combines global RF sensing, software, managed operations and deployable systems to detect, characterize and understand satellite and terrestrial activity. Solutions include enterprise software applications, portable form factors that can be deployed anywhere and persistent global RF signal monitoring and geolocation through its KnownSpace Network of over 20 locations and 190 sensors worldwide—the largest commercially owned, commercially operated (COCO) RF sensor network.

Due to security related, competitive and other considerations, no additional information will be provided.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low- cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

LIBRA-linked wallets tied to Kelsier Ventures have fallen from nearly $300 million in tracked holdings in February 2025 to about $2 million, according to blockchain analytics firm Arkham.

Summary

Arkham says Kelsier-linked wallets now hold about $2 million, down from nearly $300 million today. Over 1,000 addresses were originally linked to Hayden Davis and Kelsier Ventures during February 2025. Most of the original wallet value came from LIBRA tokens and extracted USDC and SOL. A U.S. judge dismissed the LIBRA investor class action with prejudice on September 29, 2026. Separate criminal proceedings tied to LIBRA continue in Argentina despite the U.S. civil case dismissal. Arkham said on Oct. 5 that it had identified more than 1,000 addresses belonging to Kelsier Ventures and Hayden Davis when it first published the wallet cluster in February 2025.

At the time, the addresses held close to $300 million, with most of the value coming from LIBRA tokens. Arkham now puts the remaining value across the tracked cluster at approximately $2 million.

ARKHAM FOUND 1,000 KELSIER VENTURES ADDRESSES

In February 2025 we identified over 1,000 addresses belonging to Kelsier Ventures (Hayden Davis). We were the first to publish the full set.

Those addresses held almost $300M at the time, mostly LIBRA coin. They now hold only $2M. pic.twitter.com/dq3eRSeVs2

— Arkham (@arkham) October 5, 2026 The change in wallet value does not by itself show where the difference went. Token prices, transfers between addresses, sales, liquidity movements and changes in Arkham’s tracked holdings can all affect an entity balance. Arkham’s Oct. 5 post did not provide a transaction-by-transaction breakdown explaining the decline.

Kelsier’s LIBRA wallets once held nearly $300 million Arkham first reported the Kelsier wallet cluster on Feb. 19, 2025, five days after LIBRA launched.

Its original analysis divided the identified addresses between a LIBRA entity containing wallets tied to the token and a separate Kelsier Ventures entity for addresses not directly associated with the project.

Across both groups, Arkham valued the holdings at nearly $300 million. Most of the amount consisted of LIBRA, while approximately $100 million was held in USDC and SOL that Arkham said had been removed from LIBRA liquidity pools.

Arkham described itself at the time as the first blockchain analytics service to publish the full set of more than 1,000 linked addresses.

The company identified Davis as the person behind Kelsier Ventures. A recent U.S. federal court opinion describes Kelsier Labs LLC, doing business as Kelsier Ventures, as a family-run firm incorporated under Texas law in 2021, with Hayden Davis serving as chief executive.

LIBRA launched on Solana on Feb. 14, 2025. Argentine President Javier Milei posted the token contract and promoted the accompanying Viva La Libertad project shortly after launch, according to the subsequent federal court record.

Investor demand pushed the token sharply higher before its price collapsed within hours. Milei later removed his post and said he had not been aware of the project’s details.

As previously reported, LIBRA reached a multibillion-dollar valuation before collapsing shortly after Milei’s post. Davis later acknowledged that he controlled funds connected to the project while denying that LIBRA was intended as a scam.

U.S. LIBRA lawsuit was dismissed days before Arkham update Arkham’s latest wallet disclosure comes less than a week after a major U.S. civil case involving Kelsier Ventures ended.

U.S. District Judge Jennifer L. Rochon ruled on Sept. 29 that the amended investor complaint against Kelsier, Davis family members, former Meteora CEO Benjamin Chow and other defendants could not proceed.

The case, Hurlock v. Kelsier Ventures, had accused the defendants of fraud, conspiracy, violations of the Racketeer Influenced and Corrupt Organizations Act, New York consumer law violations and unjust enrichment.

For Kelsier and the Davis defendants, the judge dismissed the RICO counts for failure to state a claim. Other claims against them were dismissed because the court found it lacked personal jurisdiction.

Claims against Chow were dismissed for failure to state a claim, while Dynamic Labs secured dismissal of claims brought against Meteora.

Rochon denied the plaintiffs’ request to file a second amended complaint and dismissed the case with prejudice, directing the clerk to close it. LIBRA class action was dismissed after the court rejected the plaintiffs’ RICO and fraud theories.

The ruling did not amount to a judicial finding that every disputed event around LIBRA’s launch did or did not happen. The court decided whether the plaintiffs’ allegations met the legal and jurisdictional requirements needed for their claims to continue.

The original class action had been filed in New York state court in March 2025 before being removed to federal court in May.

Frozen LIBRA-linked funds became part of the legal fight Wallet tracing played a role in the LIBRA litigation long before Arkham published its latest $2 million figure.

In May 2025, Circle froze approximately $57 million in USDC held in addresses tied to the dispute after a U.S. court order.

Crypto.news previously covered the $57 million USDC freeze tied to the LIBRA case, which applied to two addresses while investors pursued claims against Kelsier and related defendants.

The New York federal court later lifted its asset restraints in 2025. The Sept. 29, 2026 dismissal subsequently closed the underlying U.S. class action.

The current $2 million Arkham figure should not be read as a direct comparison with only the assets once frozen by the court. Arkham’s entity cluster covers a much larger set of addresses identified as connected to Kelsier Ventures and LIBRA.

Its February 2025 estimate included LIBRA tokens, stablecoins, SOL and other assets spread across more than 1,000 addresses.

Arkham’s Oct. 5 post does not say that $298 million was transferred out of the wallets in cash terms, nor does it identify the balance change as realized profit, investor recovery or seized funds.

Argentina’s LIBRA investigation remains separate The end of the U.S. civil lawsuit has not closed the separate criminal investigation in Argentina.

Argentina’s federal prosecutor’s office said in March that federal prosecutor Eduardo Taiano remained in charge of the investigation and was continuing work on evidence connected to LIBRA.

Prosecutors have been examining the circumstances surrounding the token’s creation and launch, including possible fraud, influence trafficking, bribery and abuse of authority.

Digital assets have already been frozen as part of that inquiry. In August 2025, prosecutors announced that an Argentine federal judge ordered the freezing of 323,275 USDT held across two addresses identified during the investigation.

Prosecutors said those addresses had received funds from a multisignature wallet examined in the case. Investigators linked activity in that wallet to the period between December 2024 and February 2025.

A separate prosecution request had sought to freeze nearly 44.6 million USDC connected to the inquiry before the U.S. court froze related stablecoin addresses in May 2025.

The Argentine prosecutor’s office said its technical investigation included analysis of electronic devices seized during the case. A final forensic report was delivered to prosecutors in January 2026 and added to the judicial case-management system in February.

The Sept. 29 U.S. ruling does not resolve those Argentine proceedings.

Arkham continues tracking the remaining Kelsier wallets Arkham’s public entity page continues to group wallets it attributes to Kelsier Ventures, allowing changes in token holdings and transfers to be monitored on-chain.

The analytics company has not said in its latest update that the approximately $2 million still visible represents all assets controlled by Davis or Kelsier Ventures outside the addresses it has identified.

Its February 2025 research was similarly limited to wallets Arkham had attributed to the entity.

Earlier reporting around LIBRA showed why attribution can change as investigators connect additional addresses. Blockchain researchers including Arkham, Nansen and other analytics firms spent months tracing wallets tied to the launch, liquidity pools and subsequent token movements.

Nansen tracked large profits and losses among LIBRA traders after the token’s rapid collapse, while separate investigations focused on early wallets and liquidity providers.

Arkham’s latest update leaves the identified Kelsier cluster at roughly $2 million compared with nearly $300 million when the firm first disclosed the addresses in February 2025.

According to the official announcement, the on-chain burn of GateToken (GT) for Q3 2026 has been successfully completed. A total of 1,987,321.2431520 GT has been transferred to the burn address, with a total burn value exceeding $22.35 million.

On-chain transaction details can be viewed at: https://etherscan.io/tx/0x4d0e1a6c996f1e9720a1b87f9d12999eee65f0ee83c7f61456fc5992b03cb5e2

Key Details of This Burn:

Burned amount this round: 1,987,321.2431520 GT Burn value this round: over $22.35 million Total burned to date: 191,934,541 GT Total burned value: over $1.504 billion (calculated based on the quarterly average price) GT is the core platform token of Gate and the native asset of Gate Chain. As the utility token and gas fee token on Gate Chain, GT plays a fundamental role in powering the network’s core transfer infrastructure. Since the Gate Chain mainnet launch in 2019, GT has implemented a sustained deflationary mechanism. The total token supply has been significantly reduced from its initial 300 million, with an overall reduction of approximately 63.98%.

As Gate continues to expand its platform, its ecosystem is extending beyond digital asset trading into a broader range of Web3 applications. Gate now serves more than 61 million users globally and supports over 5,300 crypto assets alongside 12,800+ stocks and ETFs, while continuing to strengthen infrastructure such as Gate Chain and Gate Layer. Across on-chain trading, asset issuance, and application development, products including Gate Perp DEX, Gate Fun, and Gate Meme Go are being rolled out, while AI products such as Gate.AI and Gate for AI Agent are driving more intelligent applications into the Web3 ecosystem.

Amid this development, the fundamentals supporting GT are also continuing to strengthen. The growth of Gate’s user base, product ecosystem, and on-chain applications is creating broader real-world utility for GT, while the ongoing token burn mechanism further optimizes its supply structure. As a result, GT’s long-term development is becoming more closely linked to the overall growth of the Gate ecosystem and its deflationary process, with its underlying value support gradually extending beyond platform benefits to broader ecosystem development.

In terms of market performance, GT has maintained strong upward momentum recently. Data shows that GT has gained 32.49% over the past 30 days and 63.63% over the past 90 days, demonstrating robust market performance. As the ecosystem continues to expand and the burn mechanism continues to advance, GT’s market attention and foundation for long-term value have also been further strengthened.

Looking ahead, Gate will continue to advance innovation in Web3 infrastructure and ecosystem applications, expand the real-world utility of GT across on-chain trading, network interactions, and other use cases, and remain committed to implementing the GT burn mechanism to further optimize the token’s supply structure. By advancing ecosystem expansion and deflationary mechanisms in tandem, Gate will further strengthen the utility foundation of GT, provide users with richer ways to participate in Web3, and build stronger support for GT’s long-term development.

Read the Full Report here.

About GateGate, founded in 2013 by Dr. Han, is one of the world’s leading cryptocurrency and integrated financial services platforms. Serving over 61 million users globally, it supports trading across 5,300+ digital assets and 12,800+ stock assets, while providing access to a comprehensive range of TradFi assets, including metals, stocks, indices, forex, and commodities, delivering users a one-stop, multi-asset trading experience and blockchain-related services. As an industry benchmark, Gate was among the first platforms to implement 100% Proof of Reserves. Its ecosystem includes Gate Wallet, Gate Ventures, Gate for AI Agent, and a wide range of products and services.

For more information, please visit: Website | X | Telegram | LinkedIn | Instagram | YouTube

Disclaimer:This content does not constitute an offer, solicitation, or recommendation. You should always seek independent professional advice before making investment decisions. Note that Gate may restrict or prohibit certain services in specific jurisdictions. For more information, please read the User Agreement.

Disclaimer

BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Sui price has climbed 4.43% to $1.23 as Mysten Labs co-founder Adeniyi Abiodun outlined a strategy centered on global payments, stablecoins and AI-agent transactions, while traders watch $1.27 as the next technical hurdle.

Summary

SUI rose 4.43% to $1.23 today as traders watched $1.27 for potential bullish breakout confirmation. Sui has processed more than $1 trillion in stablecoin transfers since August 2025, foundation says. Google lists Mysten Labs among collaborators behind AP2, its open protocol for AI-driven payments systems. USDsui launched in March through Stripe-owned Bridge, giving Sui a native dollar for payments applications. Analysts see $1.27 as immediate resistance, while a $2 target remains conditional on breakout confirmation. Wu Blockchain published the interview on Oct. 5, with Abiodun arguing that Sui should be viewed as payment infrastructure capable of moving money globally instead of simply another Layer 1 blockchain.

CoinGecko data showed SUI near $1.23 during the session, with a market value close to $5 billion and roughly $878 million in 24-hour trading volume. The token had traded between approximately $1.17 and $1.26 during the day.

Abiodun said Sui’s long-term ambition was to compete with traditional payment infrastructure, going as far as saying its goal over the next several years is to “replace SWIFT.” The statement represents Mysten Labs’ long-term view and does not amount to a forecast that Sui will displace the global bank messaging network.

Sui price is closing in on the $1.27 level On the weekly chart, SUI is trading above the upper Bollinger Band near $1.19, while the 20-week middle band sits around $0.83 and the lower band near $0.46.

Price moving above the upper band shows stronger upside momentum compared with its recent weekly range, though it leaves SUI extended above its 20-week average. The immediate $1.19-$1.25 area remains important because SUI is testing the upper band and recent weekly highs.

Sui price chart, source: TradingView The Relative Strength Index stands at 58.71, above its signal average near 44.19. RSI has recovered above the neutral 50 level but remains below the commonly watched overbought threshold of 70.

Crypto analyst Ali Martinez said on Oct. 2 that SUI had repeatedly formed parallel consolidation channels before breaking higher since Sept. 12. He identified $1.27 as the next level to watch, saying an hourly close above it “could confirm another bullish breakout.”

Price has since moved closer to that threshold without clearly breaking it. CoinGecko showed the token reaching a 24-hour high near $1.26, leaving Martinez’s $1.27 trigger just above the current market.

A second analyst, Celal Kucuker, said a bull flag was approaching resistance. He argued that a break of the pattern during October could bring $2 into view.

$SUI
The bull flag is getting close to a breakout.

If the red resistance line breaks this month, $2 could come quickly.

In a bull market, $10+ looks technically very achievable from here. pic.twitter.com/7TpnoTLCw4

— Celal Kucuker (@CelalKucuker) October 4, 2026 Kucuker’s longer-term call for prices above $10 was explicitly tied to a future bull-market scenario. It remains an analyst projection, not a confirmed target supported by current price action.

For now, $1.27 is the closer test. A sustained move above it would place SUI beyond the level Martinez identified, while a return below roughly $1.19 would move price back inside the weekly Bollinger Band.

Stablecoins are becoming central to Sui’s payment push Abiodun described stablecoins as one of the strongest current uses for blockchain payments because they can operate continuously and settle outside conventional banking hours.

Sui Foundation said in May that the network had processed more than $1 trillion in stablecoin transfer volume since August 2025. The same update introduced gasless transfers for supported stablecoins, allowing qualifying peer-to-peer transactions to execute without users holding SUI for gas.

The feature initially covered assets including USDsui, USDC, SuiUSDe, AUSD, FDUSD, USDB and USDY. Sui’s documentation says eligible transfers can use a zero gas price and budget when they meet the network’s allowlist requirements.

USDsui gives the network its own native dollar asset. Sui Foundation announced its mainnet launch on March 4 through Bridge, the stablecoin infrastructure company owned by Stripe. The token was built for payments, decentralized finance and cross-border transactions.

As previously reported, Sui’s USDsui launch brought a native stablecoin to its payment and DeFi ecosystem after the network processed more than $111 billion in stablecoin transfers during January alone.

Abiodun said USDsui had reached roughly $75 million and named stablecoin liquidity as one metric Mysten Labs will watch when measuring future network adoption.

Recent integrations have extended the payment strategy beyond DeFi. Daya integrated Sui as settlement infrastructure in September, using gasless stablecoin transfers across products serving businesses and developers in Nigeria. The company plans to expand into South Africa, Ghana and Kenya.

RedotPay provides another payment connection, though its official April announcement is narrower than the translated interview suggested. Sui Foundation said RedotPay added support for SUI and native USDC on Sui, giving users access to assets through a payment network that supports Apple Pay and Google Pay. The official release does not identify USDsui as part of that initial integration.

AI agents form the second part of Sui’s strategy Abiodun expects AI agents to become a major source of blockchain transactions as software begins making payments, purchasing services and moving funds without a person manually initiating every transfer.

His view has some support from Sui’s work with Google. Google announced the Agent Payments Protocol, or AP2, in September 2025 and listed Mysten Labs among more than 60 payments and technology organizations helping develop the open standard.

AP2 is designed to let AI agents initiate payments under verifiable user authorization across different payment systems. Google’s list includes companies such as Mastercard, PayPal, Coinbase, Revolut and Worldpay alongside Mysten Labs.

Sui joined Google’s AP2 effort around programmable payments for AI agents, placing the blockchain among projects testing how autonomous software could interact with digital money.

Sui’s current AI infrastructure combines several products. Walrus handles decentralized storage, Seal manages programmable access controls and Nautilus supports verifiable computing, while Sui coordinates transactions and policies on-chain.

Abiodun argued that such tools could help AI systems prove where information came from and whether it was changed before an agent makes a decision or payment.

Sui tested that type of automated activity in July through programmable tunnels. The foundation reported a peak of 6,086,766 transactions per second during a public experiment involving AI agents, games, payments and chat. The result came from off-chain programmable channels that settle back to Sui mainnet, not normal base-layer transaction throughput.

Sui still faces a gap between payments growth and DeFi TVL Abiodun acknowledged the decline in Sui’s total value locked during the interview while arguing that stablecoin use, institutional integrations and network activity deserve attention alongside TVL.

Current DefiLlama data place Sui DeFi TVL near $550 million, with stablecoin market capitalization close to $482 million. The tracker recorded roughly 25.3 million network transactions over the latest 24-hour period.

The interview referenced a previous TVL level of approximately $4 billion before a decline toward $1 billion. The $4 billion figure could not be matched to the current DefiLlama dataset reviewed for this report, so it remains attributed to the interview.

Governance remains another part of Sui’s recent history. After the $223 million Cetus exploit in May 2025, validators coordinated around frozen attacker funds and later voted on a protocol upgrade to recover them.

Sui Foundation reported that validators representing 90.9% of stake supported the recovery proposal, with the foundation’s stake excluded from the vote. Approved funds were moved to a multisignature wallet for return under Cetus’ recovery plan.

Abiodun said Mysten Labs and the Sui Foundation cannot independently order validators to freeze addresses, describing such actions as decisions that require validator coordination.

Price traders are now watching a much shorter-term question. SUI is sitting near $1.23 after its latest gain, while the weekly RSI remains below overbought territory and $1.27 stands just above the current trading range.

Martinez’s setup requires an hourly close above $1.27 before his proposed breakout is confirmed. Kucuker’s $2 scenario requires a separate bull-flag resistance break during October, while his $10-plus forecast depends on the much less certain condition of a future bull market.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Company has provided four rounds of bill credits while continuing investments in PFAS treatment and water quality improvements across Indiana

, /PRNewswire/ -- Indiana American Water announced that it is providing a fourth bill credit to customers this month following the company's receipt of proceeds from settlements reached with manufacturers of per- and polyfluoroalkyl substances (PFAS). With this latest credit, Indiana American Water will have returned a total of over $25.5 million to customers statewide of PFAS settlement distributions.

Since November 2025, eligible water customers will have received nearly $75 per account in PFAS settlement credits. For the average residential customer, that amount exceeds the cost of a typical monthly water bill, based on average usage of 4,000 gallons per month and an average monthly bill of approximately $55.

Credit       

Timing                       

Amount Per Customer

First Credit    

November 2025  

$13.20

Second Credit   

January 2026           

$39.43

Third Credit  

July-August 2026     

$10.64

Fourth Credit   

October 2026               

$11.65

Total                     

$74.92

The credits distribute settlement proceeds Indiana American Water received from PFAS manufacturers through a customer bill credit mechanism approved by the Indiana Utility Regulatory Commission (IURC). This streamlined approach allows settlement funds to be returned quickly, equitably and transparently through automatic bill credits that are applied equally among eligible tariffed water customer accounts. The company plans to continue providing additional bill credits as future settlement payments are received and approved for distribution.

"Indiana American Water remains committed to returning these settlement proceeds directly to our customers while continuing to invest in the long-term protection of safe, clean, reliable and affordable drinking water across Indiana," said Barry Suits, president of Indiana American Water. "These credits provide a direct customer benefit from the settlements, while our company continues making significant investments in monitoring, treatment technologies and infrastructure improvements designed to address contaminants of emerging concern such as PFAS. We believe customers should receive the benefit of these settlement funds as quickly and efficiently as possible."

The credits are not based on whether PFAS has ever been detected in a customer's water supply, and Indiana American Water remains committed to meeting all state and federal drinking water standards while proactively addressing evolving PFAS regulations.

Indiana American Water has been a leader in PFAS treatment and water quality investments in Indiana. In January 2026, the company announced operation of Indiana's first drinking water treatment system specifically designed to remove PFAS at its Charlestown Water Treatment Plant. The company also has advanced PFAS treatment projects underway in Terre Haute and is evaluating additional treatment investments in other communities as part of its broader strategy to address emerging contaminants and comply with future regulatory requirements.

PFAS are a group of manufactured chemicals that have been used in consumer products and industrial applications for decades. Indiana American Water, along with numerous other water utilities nationwide, participated in multi-district litigation (MDL) proceedings seeking damages from manufacturers of PFAS chemicals. Settlement agreements provide payments over multiple years, allowing utilities to return proceeds to customers as funds are received.

Customers interested in learning more about PFAS, including what these compounds are, how they are regulated and the steps Indiana American Water is taking to address them, can visit the company's PFAS information webpage at Indiana American Water PFAS Information. Customers can also view annual Water Quality Reports for their local community, which provide detailed information about drinking water quality, testing and compliance with state and federal standards.

About American Water
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 19 military installations. American Water's approximately 7,000 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.

About Indiana American Water
Indiana American Water, a subsidiary of American Water, is the largest regulated water utility in the state, providing high-quality and reliable water and wastewater services to approximately 1.5 million people.

SOURCE American Water

Increases total implied consideration by 25% to US$5.00 per Aurora Share, representing a premium of 86% to Aurora's Unaffected Share Price

Increases Cash consideration by 33% to US$1.00 per Aurora Share, which represents approximately 20% of the consideration mix

Increases Share Consideration to 0.4013 Curaleaf shares per Aurora Share and increases the Cap Price by 20% to US$6.00 per share

Enhanced proposal developed solely from publicly available information; Curaleaf remains committed to engaging with Aurora in a formal due diligence process and urges Aurora's Board to engage in good faith discussions regarding the Enhanced Offer

Enhanced Offer continues to provide Aurora Shareholders with the opportunity to become owners of the premium global cannabis platform and participate in the significant long-term upside of the combined company

, /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today announced that it will file a Notice of Variation and Change to increase its offer (the "Enhanced Offer") to acquire all of the issued and outstanding common shares (the "Aurora Shares") of Aurora Cannabis Inc. ("Aurora") for consideration consisting of subordinate voting shares of Curaleaf (the "Curaleaf Shares") and cash.

Under the terms of the Enhanced Offer, Aurora shareholders would receive total implied consideration of US$5.00 per Aurora Share, comprised of 0.4013 Curaleaf Shares (the "Share Consideration") plus US$1.00 cash (the "Cash Consideration", and collectively with the Share Consideration, the "Amended Consideration") based on Curaleaf's U.S. dollar equivalent closing share price of C$14.21 (C$1.00 = US$0.7015) on October 2, 2026. Based on Aurora's 30-day volume weighted average price ("VWAP") of US$2.75 as of August 10, 2026 (the day before Curaleaf announced its intention to make its initial Offer (the "Unaffected Share Price"), the Enhanced Offer represents a premium of 86% to Aurora's Unaffected Share Price. Excluding the value of the cash and cash equivalents that Aurora has on its balance sheet, including its subsequent equity issuances pursuant to its at-the-market ("ATM") program issued during its fiscal first quarter, the Enhanced Offer represents a premium of 217% to the ex-cash Unaffected Share Price.  

The Enhanced Offer will also increase the Offer's maximum consideration per Aurora Share from US$5.00 to US$6.00 (the "Cap Price"). The Cap Price would represent a premium of 118% to Aurora's Unaffected Share Price and a 295% premium to the ex-cash Unaffected Share Price.

Boris Jordan, Chairman of the Board and Chief Executive Officer of Curaleaf, stated:

"Over the past several weeks, we have met with a significant percentage of Aurora's shareholder base, all of whom are supportive of the strategic rationale for the deal. This increased offer reflects careful consideration and shareholder input, demonstrating our continued commitment to reaching a successful outcome.

"Importantly, we are enhancing our proposal despite Aurora's refusal to engage and provide access to customary due diligence. We view this as a significant good-faith step that demonstrates our conviction in the merits of a combination and the value creation opportunity it represents.

"We have demonstrated our willingness to act in the best interest of shareholders. While this is not how we would expect to engage in a sale process, we are prepared to act because we believe strongly in the value creation opportunity. Importantly, if Aurora is providing diligence access to other parties, shareholders deserve a fair and open process that includes Curaleaf."

A combination of Curaleaf and Aurora would create the global cannabis leader, with operations across 17 countries, more than US$1.5 billion of last-twelve-month ("LTM") revenue, nearly US$350 million of LTM Adjusted EBITDA and at least US$40 million of expected annual cost synergies. Aurora shareholders would retain exposure to Aurora's international business while gaining ownership in Curaleaf's leading U.S. platform and future regulatory upside.

The combined company would be a larger, more diversified global cannabis platform with a pro forma market capitalization in excess of US$3 billion, with its scale, diversity and enhanced liquidity providing a significantly lower cost of capital than Aurora has today, providing Aurora shareholders with greater opportunities to capitalize on the global cannabis sector.

Curaleaf will be filing a Notice of Variation, Change and Extension (the "Notice of Variation and Change") to its Offer to Purchase and Circular and related offer materials to reflect the Enhanced Offer with the applicable Canadian securities regulatory authorities and a new Registration Statement on Form F-80 with the U.S. Securities and Exchange Commission. The Notice of Variation and Change is expected to be filed promptly. Aurora shareholders and other interested parties can find additional information regarding Curaleaf's Enhanced Offer, including materials and instructions on how to tender their shares, at grow.curaleaf.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Although we do not believe required, as a sign of our commitment to the Enhanced Offer, the Notice of Variation and Change will also include the pro forma financial statements that Aurora suggests should be provided. The Notice of Variation and Change will also extend the Expiry Time under the Offer from 5:00pm (Mountain Time) on December 1, 2026 to 11:59pm (Mountain Time) on December 4, 2026.

IMPORTANT INFORMATION

This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The Offer by Curaleaf to purchase all outstanding common shares of Aurora is made solely by the Offer to Purchase and Circular dated August 18, 2026, as amended by the Notice of Variation and Change and as may be further amended or supplemented.

SECURITY HOLDERS ARE URGED TO READ THE NOTICE OF VARIATION AND CHANGE AS WELL AS THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENTS ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Free copies are available at www.sedarplus.ca, www.sec.gov or by contacting the Information Agent, Carson Proxy Advisors, at 1-800-530-5189 (toll-free), 416-751-2066 (local/text), or [email protected].

NOTICE TO U.S. SHAREHOLDERS

The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country.

Investors should be aware that the bidder or its affiliates, directly or indirectly, may bid for or make purchases of the issuer's securities subject to the offer or of the issuer's related securities, or of the bidder's securities to be distributed or of the bidder's related securities, during the period of the tender offer, as permitted by applicable Canadian laws or provincial laws or regulations.

Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the U.S. Securities Act of 1933 and a Tender Offer Statement on Schedule 14D-1F under the U.S. Securities Exchange Act of 1934 and will promptly be filing amendments to both to reflect the Enhanced Offer. The Offer is being conducted in accordance with Section 14(e) of the Exchange Act and Regulation 14E.

THE OFFER AND THE OFFEROR SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY U.S. STATE SECURITIES COMMISSION, NOR HAS ANY SUCH AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The Curaleaf Shares to be issued under the Offer have not been registered or otherwise qualified for offer and sale in certain U.S. states where shareholders may reside. No offer is made in those states except to qualifying Exempt Institutional Investors as described in the Offer to Purchase and Circular.

FORWARD-LOOKING INFORMATION

This document contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of applicable U.S. securities laws. Such statements relate to, among other things, the expected benefits, timing, and effects of the Offer, the timing for filing of the Notice of Variation and Change, and anticipated synergies from a combination of Curaleaf and Aurora. Forward-looking statements can often be identified by words such as "believes," "expects," "anticipates," "may," "will," or similar expressions.

Actual results may differ materially due to risks including: changes in general economic conditions; failure to satisfy conditions to the Offer; failure to realize anticipated synergies; fluctuations in foreign exchange and interest rates; regulatory changes; and other risks described under "Risk Factors" in the Offer to Purchase and Circular. The safe harbor for forward-looking statements does not apply to statements made in connection with a tender offer. Security holders should not place undue reliance on forward-looking information. Curaleaf disclaims any obligation to update forward-looking information except as required by law.

AURORA INFORMATION

Information concerning Aurora herein is based solely on Aurora's publicly available filings and other public sources. Aurora has not reviewed this document. Neither Curaleaf nor its officers or directors assumes responsibility for the accuracy or completeness of such information.

ADDITIONAL INFORMATION

The disposition of Common Shares and the acquisition of Curaleaf shares may have U.S. and Canadian tax consequences; shareholders should consult their own tax advisors and review the tax disclosure contained in the Offer to Purchase and Circular which are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

About Curaleaf Holdings

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Contacts

Media Contact
Kekst CNC
[email protected] 

Investor Contact
Curaleaf Holdings, Inc.
[email protected] 

Shareholder Contact 
Carson Proxy Advisors
North American Toll Free Phone: 1-800-530-5189
Local (Collect outside North America): 416-751-2066
Email: [email protected] 

SOURCE Curaleaf Holdings, Inc.

, /PRNewswire/ -- Leidos (NYSE: LDOS) and investment firm Altaris have completed their previously announced transaction to form a scaled U.S.-based joint venture (JV) for advancing security screening at airports, borders and critical infrastructure worldwide.

Operating under the Analogic brand, the new company combines complementary security screening technologies, engineering expertise and advanced manufacturing capabilities. Leidos will retain a significant minority ownership stake in the company, maintaining its interests in a critical national security market.

"This JV creates an American innovator with the technology, talent and scale to address rapidly evolving global security screening needs," said Leidos Chief Executive Officer Tom Bell. "Its launch also sharpens our focus on the growth engines driving our NorthStar 2030 strategy."

In parallel with the mission of the Analogic JV, Leidos will continue its work across the broader aviation ecosystem, including modernizing airports and air traffic systems to help move people safely and efficiently around the world.

"The strategic combination of these two businesses into one reinforces our commitment to the important national security missions and markets we serve," Bell said.

About Leidos

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with approximately 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.leidos.com.

About Analogic

Analogic, headquartered in Salem, New Hampshire, is a global provider of advanced imaging, detection, automation, and power technology solutions. The company designs, develops, manufactures, and supports a comprehensive portfolio of solutions for aviation security, ports and borders, critical infrastructure, healthcare, and industrial markets worldwide. Backed by decades of innovation and a global installed base, Analogic combines advanced imaging, artificial intelligence, precision power, automation, and lifecycle support capabilities to help customers meet evolving operational and regulatory requirements. For more information, visit www.analogic.com.

About Altaris

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $9+ billion of equity capital. For more information, visit www.altariscap.com.

Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this release depending on a variety of factors, including, but not limited to: ; the future operational and financial performance of the new joint venture company; the ability of the new joint venture company to successfully integrate the SES business and Analogic at all or otherwise in accordance with any anticipated timeline; the ability of the new joint venture company to service its indebtedness;  developments in the U.S. government defense and non-defense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, future delays in the U.S. government budget process, or the U.S. government's failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; deterioration of economic conditions or weakening in credit or capital markets; uncertainty in the consequences of current and future geopolitical events; inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company; our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to respond rapidly to emerging technology trends, including the use of artificial intelligence; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of an epidemic, pandemic or similar outbreak may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer, disposal and other processing, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts; the failure of our inspection or detection systems to detect threats; the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to declare or increase future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements; our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects; our ability to successfully integrate acquired businesses; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks described in our Securities and Exchange Commission filings.

Media Contact:

Victor Melara
Senior Media Relations Manager
703.431.4612
[email protected]

SOURCE Leidos

New offerings bring beverage culture's biggest trends to life through distinctive new flavors, expanded energy choices and updates to iconic brands

, /PRNewswire/ -- Keurig Dr Pepper (NASDAQ: KDP) today unveiled a first look at its 2027 beverage innovation pipeline ahead of the 2026 National Association of Convenience Stores (NACS) Show. The lineup delivers what consumers want most: familiar favorites, reimagined; a bigger, bolder energy lineup; and refreshed iconic brands.

Photo Credit: Keurig Dr Pepper

Photo Credit: Keurig Dr Pepper

Photo Credit: Keurig Dr Pepper

Photo Credit: Keurig Dr Pepper

"Beverages are one of the strongest drivers of traffic and basket growth for convenience retailers, and innovation is what keeps shoppers engaged," said Jeff Tabor, Chief Customer Officer at Keurig Dr Pepper. "Our 2027 pipeline brings together breakthrough energy varieties, culturally relevant flavors and meaningful investments in some of the industry's most iconic brands. Backed by our broad portfolio and route-to-market capabilities, these innovations are designed to create excitement, spark discovery and help retailers capture incremental sales across the beverage category."

Familiar Favorites, Reimagined

KDP's research shows that younger consumers are exploring a wider range of beverage categories and flavors, while remaining drawn to the nostalgia and familiarity of brands they know and love. Carbonated Soft Drinks remain the largest non-alcoholic beverage segment, and innovation continues to drive category dollar growth. Building on a track record that includes delivering the #1 CSD innovation in each of the past three years1, KDP is introducing the following fresh twists on familiar favorites, all of which are available in both Regular and Zero Sugar varieties:

Dr Pepper® Ice Cream Float blends Dr Pepper's signature 23 flavors with a creamy vanilla ice cream flavor and rich notes of caramel and butterscotch for an everyday treat take on the beloved float. Launching nationwide as a permanent offering, the flavor will be available in cans and 20 oz. bottles beginning February 2027, with fountain and frozen dispensed formats arriving mid-year.
   7UP® Miami Vice™ combines refreshing lime-lemon, sweet strawberry daiquiri, and creamy pina colada flavors for a tropical soda experience inspired by the classic frozen cocktail. The limited-time offering arrives nationwide in June 2027.
   7UP® Shirley Temple, one of the brand's most successful recent flavor platforms, returns for the holiday season as a limited-time offering. Featuring the nostalgic flavors of cherry and pomegranate, the fan-favorite flavor will roll out with expanded immediate-consumption availability through a new 20 oz. package in 2027.
   Canada Dry® Raspberry Lemonade combines the flavors of raspberry and lemonade with the crisp refreshment of Canada Dry for a bright, seasonal twist beginning in Spring 2027. A Bigger, Bolder Energy Lineup for 2027

Energy remains one of the fastest-growing areas in beverages, with innovation and limited-time offerings driving nearly three-quarters of category growth2. In 2027, KDP will distribute more than 25 new items across its energy brand portfolio, spanning permanent additions, limited-time releases, distinctive collaborations and new formats designed to meet growing demand for flavor exploration and variety. Highlights from the Company's owned energy brand, GHOST®, and energy brand partners include:

Building on the success of its partnership with KDP, GHOST® - now a $1 billion brand at retail - will make GHOST® Energy x 7UP® and GHOST® Energy x A&W® permanent offerings in 2027 following the popularity and strong retail performance of the 2026 limited-time releases. The brand will also launch GHOST® Energy Sour Strips Appleberry™, a sweet-and-sour blend of green apple and strawberry, nationwide in January, followed by the limited-time GHOST® Energy Blueberry Cream, a first-to-market flavor requested by consumers that pairs tangy blueberry with sweet, creamy vanilla for a nostalgic yogurt-inspired taste.
   Bloom Energy™ will introduce a new lineup of iconic treats, featuring three flavors inspired by childhood favorites. Strawberry Shortie, available beginning in October 2026, combines sweet swirls of strawberry and vanilla cream flavors reminiscent of a classic ice cream truck treat, while Cotton Candy and Lemon Freezie, arriving in January 2027, deliver playful takes on blue cotton candy and frozen lemonade respectively.
   C4 Energy® will expand its zero-sugar Cereal's Most Wanted lineup in January 2027, introducing Cocoa Loco in 16-ounce cans and launching new 8.4-ounce mini can formats for Cereal Killer, Jacked Apple Crunch and Buzzin' Honey O's. The great Breakfast Heist of 2027 is upon us.   Refreshing Iconic Brands

While consumers are exploring more flavors than ever, they continue to return to the brands they know and trust. KDP is investing in iconic brands like 7UP and Sunkist with updates that enhance taste, evolve with changing consumer preferences and strengthen their presence across the physical and digital shelf.

7UP®recently unveiled its most significant brand evolution in more than 15 years, featuring a consumer-preferred lime-forward formula, refreshed packaging, a modernized logo and an updated visual identity across select varieties. The refresh reflects a renewed investment in the iconic brand and reinforces 7UP's distinctive position within the category.
   Sunkist® will introduce updated graphics and a refreshed recipe in Q1 2027. The renovation builds on the brand's signature citrus flavor with an improved orange taste for a more fruit-forward experience for today's consumer. In addition to the innovations featured in this release, attendees at the 2026 NACS Show in Las Vegas will get an exclusive preview of upcoming consumer-inspired innovations from across KDP's portfolio of owned and partner brands, including Snapple, Electrolit, Polar, La Colombe, Vita Coco and more.

About Keurig Dr Pepper
Keurig Dr Pepper (Nasdaq: KDP) is a leading beverage company with more than 150 owned, licensed and partner brands that meet a wide range of needs and occasions. Our North American refreshment beverage business holds leadership positions across carbonated soft drinks, water, juice and mixers with a portfolio of iconic brands such as Dr Pepper®, Canada Dry®, Mott's®, A&W®, Peñafiel®, GHOST®, 7UP®, Snapple®, Clamato® and Core Hydration®. Our global coffee business spans more than 100 markets and includes the leading Keurig® single‑serve brewing system in the U.S. and Canada, along with powerhouse brands such as Peet's, L'OR and Jacobs, and other regional coffee leaders. Our more than 50,000 employees aim to enhance the experience of every beverage and coffee occasion while making a positive impact for people, communities and the planet. Learn more at www.keurigdrpepper.com and follow us @KeurigDrPepper on LinkedIn and Instagram.

Media Contact:
Xenja Lindberg
[email protected]

1 Source: Circana Total US Multi-Outlet + Convenience, Calendar Year 2025, 2024 and 2023
2 Source: Circana POS Energy Drink Aisle, 2024 vs. 2025.

SOURCE Keurig Dr Pepper

New business unit designed to deliver enterprise-grade AI transformation to emerging enterprises that generate $1 billion to $5 billion in annual revenue, building toward Global 2000 scale, through a dedicated, right-sized operating model built for speed

, /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading AI builder and technology services provider, today announced the launch of Cognizant Activate, a new business unit designed to help emerging enterprises harness AI and accelerate transformation. Cognizant Activate brings the depth of Cognizant's AI Builder capability, proven with the world's largest companies, together with a purpose-built operating model tailored to the speed, priorities and decision-making dynamics of emerging enterprises.

Cognizant is an AI Builder company www.cognizant.ai Emerging enterprises with high growth face many of the same pressures as large enterprises, including legacy technology, rising cybersecurity risk and the need to adopt AI ahead of competitors, but they require solutions that are faster to deploy and right-sized for their scale.

Cognizant Activate is expected to deliver platform-aligned, pre-configured solution kits spanning data and AI, cybersecurity, enterprise applications, cloud modernization and managed services. The business unit will operate with vertically integrated teams and a single engagement lead accountable from the first conversation through delivery. It will launch with an initial focus on financial services, healthcare, manufacturing and retail/CPG sectors, where Cognizant has deep domain expertise and an established presence serving emerging enterprises. Cognizant Activate will also draw on Cognizant's ecosystem partnerships to accelerate time-to-value for clients.

"The companies shaping tomorrow's economy are moving fast and thinking boldly, and they need a partner who will treat their transformation as consequential, not incremental," said Ravi Kumar S, Chief Executive Officer of Cognizant. "Cognizant Activate brings the same AI Builder capability that is helping to transform some of the world's largest enterprises to emerging enterprises, right-sized for their speed and scale. This is how our clients activate growth with AI."

Cognizant Activate is built around the idea that emerging enterprises aren't looking for a scaled-down version of an enterprise engagement. They want a partner that can build AI into how they operate today, not add it as a future roadmap item. Cognizant's approach combines pre-built AI accelerators, compressed implementation timelines and commercial models designed for high-growth economics.

"Emerging enterprises with high growth want enterprise-grade capability without enterprise-level complexity and cost," said Mohammad Haque, Global Head of Intelligent Enterprise Platforms and Large Deals of Cognizant. "Cognizant Activate gives them access to our global delivery network, platform certifications and decades of industry expertise, delivered through a model built specifically for their speed and ambition."

About Cognizant
Cognizant (Nasdaq: CTSH) is an AI builder and technology services provider, building the bridge between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization's unique context into technology systems that amplify human potential, realize tangible returns and keep global companies ahead in a fast-changing world. See how at www.cognizant.ai or @cognizant.

For more information, contact:
Katrina Cheung
[email protected]

SOURCE Cognizant Technology Solutions Corporation

Credo Technology just posted its seventh consecutive quarter of triple-digit revenue growth, yet analysts still set targets well below where this volatile stock has already traded. One specific milestone in its optical business could force a dramatic rethink of where…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Credo Technology (NASDAQ:CRDO | CRDO Price Prediction) sells the connectivity that keeps AI clusters talking. Its lineup covers active electrical cables, optical DSPs, retimers and now silicon photonics. Revenue hit a record $479 million last quarter, up 115% year over year.

Shares are up 54.22% year to date but still trade well below the $308.67 52-week high. One number could change the long-term story: more than $600 million of optical revenue in fiscal 2027. So can Credo hit $350 in 2027?

What’s Holding Credo Back Right Now The biggest risk is volatility: Credo carries a beta of 3.228. Shares traded at $282.82 in mid-August and fell to $161.49 by mid-September, though recent gains of +13.24% week-over-week show a rebound.

GAAP gross margin slipped to 64.5% from 68.2% sequentially due to acquisition amortization. Goodwill jumped to $986.4 million. The largest customer accounted for 33% of revenue and the second-largest for 28%. Inventory rose to $313.1 million, and share-based compensation reached $87.98 million.

Analysts Are Bullish, but Their Targets Trail the Estimates The consensus target is $281.09. The stock carries 4 Strong Buy, 14 Buy, 1 Hold, plus 0 Sell ratings from analysts. The model’s base case is $270.13, or 18.44% upside. The scenario range runs from a bear case of $212.44 to a bull case of $335.88. Model confidence is high, at 0.9 on a 1.0 scale.

The fiscal 2028 EPS estimate has rose to $9.7049 from $8.8475 90 days ago. Over the last 30 days there were 14 upward revisions and 1 downward. Analyst sentiment is 95% bullish, yet the model may be underweighting the optical ramp.

Here’s What It Takes for Credo to Reach $350 A climb to $350 from $228.07 means a gain of 53.5%.

Given forward EPS of $7.1551, $350 amounts to a significantly higher forward multiple than the base case of $270.13, calling for additional multiple expansion.

That expansion is justified because management expects fiscal 2027 revenue growth above 85% and a non-GAAP net margin “in the vicinity of 50%”. Zero-flap optics, silicon photonics PICs and optical DSPs are each expected to top $100 million.

CEO Bill Brennan said: “Fiscal 27, I think, is just a stepping stone for where we’re going with our optical business.” OmniConnect could add “thousands of dollars of Credo content per GPU” starting in fiscal 2028.

A slowdown in hyperscaler capex poses the biggest risk, landing hard on a business where three to four customers each make up more than 10% of revenue.

The flip side is that the same expansion is lifting a whole bench of suppliers beyond the chipmakers (we covered seven of them, from power to cooling to networking, in a free report).

Where Credo Trades Today vs Its Earnings Power At $228.07, Credo’s forward multiple is reasonable for a company posting its seventh consecutive quarter of triple-digit growth. The stock is trading between its 52-week low of $86.48 and a high of $308.67.

Since January 2022, the stock has gained 1,804.81%. If the optical business delivers, today’s multiple leaves room for the rerating the bull case depends on.

$350 Is a Stretch, but Here’s Why It’s Possible Hitting $350 requires a 53.5% gain. It’s a stretch, but within reach for a stock this volatile.

Optical revenue must clear $600 million, the first 1.6T DSP revenue must arrive on schedule, and Q2 revenue must meet the $525 million to $535 million guidance. A sharp cut in AI infrastructure spending would undermine the thesis. We’ve outlined the blueprint for how Credo could reach $350 in 2027.

Contact [email protected] for any questions or corrections.

 | Source: SAIC, Inc.

RESTON, Va., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC), a leading mission integrator supporting defense, space, intelligence, and civilian agencies, today announced it has completed the acquisition of Information Security Corporation (ISC).

For more than three decades, ISC has delivered public key infrastructure (PKI), encryption, and credential management software to some of the most security-conscious organizations in government and industry, providing the critical cryptographic building blocks for confidentiality, integrity, and availability of sensitive data. Engineered with a forward-looking focus on automation and crypto-agility, ISC’s product suite helps customers modernize their cryptographic infrastructure and transition to post-quantum cryptography. The suite spans PKI and data protection solutions, including CertAgent, which has been on the National Security Agency’s Commercial Solutions for Classified (CSfC) Components List for more than a decade.

“This strategic tuck-in acquisition reflects our disciplined approach to investing in technology and capabilities that address the nation’s most critical challenges,” said Jim Reagan, Chief Executive Officer of SAIC. “Integrating ISC’s mission-proven cryptographic technologies with SAIC’s pedigree of delivering and operating robust zero-trust architectures, provides our intelligence and defense customers with the security and scalability to protect against rapidly evolving threats.”

“Joining SAIC marks an exciting new chapter for ISC and our employees,” said Jonathan Schulze-Hewett, Vice President of Development at ISC. “For more than three decades, our team has built innovative products to solve some of our customers’ most difficult security challenges. Joining SAIC gives us the opportunity to build on that work and bring ISC’s technology to more customers and more missions.”

ISC's technology is deeply embedded across the U.S. intelligence community and Department of War, supporting identity, authentication, and data protection in some of the government's most sensitive environments.

Financial terms were not disclosed. SAIC was supported by KPMG and ISC was advised by TideLock Partners.

About SAIC
SAIC® is a premier mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, intelligence, and civilian markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact: 
Caralyn Duke
[email protected]

Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com or on the SEC’s website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.